Lennox-Gastaut Syndrome

🏷

Classifications

Harrison's Part

🔗

Mappings

MONDO

MONDO:0016532 Lennox-Gastaut syndrome

MONDO:0016532 is the current Lennox-Gastaut syndrome disease concept.

NCIT

NCIT:C84816 Lennox-Gastaut Syndrome

MONDO:0016532 carries NCIT:C84816 as a cross-reference; the NCI Thesaurus concept names the same syndrome.

ICD-10-CM

ICD10CM:G40.81 Lennox-Gastaut syndrome

MONDO:0016532 carries ICD10CM:G40.81 as a cross-reference, and the ICD-10-CM code is a named Lennox-Gastaut syndrome rubric (its G40.811-G40.814 children only add intractability and status-epilepticus qualifiers).

ICD-11 Foundation

icd11f:651135242 Lennox-Gastaut syndrome

MONDO:0016532 carries icd11.foundation:651135242 as a cross-reference; the ICD-11 Foundation entity label is identical to the MONDO label.

NCIT

NCIT:C84816 Lennox-Gastaut Syndrome

MONDO:0016532 carries NCIT:C84816 as a cross-reference; the NCI Thesaurus concept names the same syndrome.

?

Discussions and Knowledge Gaps

4

Is Lennox-Gastaut syndrome a single disease with a unifying network mechanism, or a convergent electroclinical endpoint that many distinct etiologies reach when they perturb the immature brain — and what network property, if any, actually defines membership?

CONTROVERSY OPEN gap_lgs_convergent_syndrome_vs_disease

Attached to

pathophysiology#Heterogeneous Etiologic Brain Insult pathophysiology#Diffuse Thalamocortical Network Dysfunction

LGS is defined by a characteristic triad that appears despite highly diverse structural, genetic, and metabolic causes, which is why this entry models a heterogeneous insult converging on a shared network node rather than a single lesion. Whether there is a genuine unifying mechanism (a specific thalamocortical network signature that all cases share) or whether LGS is essentially a stereotyped way the immature network fails, with no deeper common cause, remains debated. The answer determines whether LGS should be modeled as one disease entity or as a syndromic label over many diseases, and whether a network-level therapeutic target could exist.

Proposed experiments

Cross-etiology network-signature comparison in LGS

EEG-functional MRI network comparison experiment

exp_lgs_shared_network_signature

Using simultaneous EEG and functional MRI across patients with LGS of distinct etiologies (structural, genetic, post-infantile-spasms), test whether slow spike-and-wave and paroxysmal fast activity recruit the same thalamocortical hubs regardless of cause, and whether a shared network signature separates LGS from other generalized epilepsies.

Readouts

Shared network recruitment

pathophysiology#Diffuse Thalamocortical Network Dysfunction

functional magnetic resonance imaging assay electroencephalography

Direction: POSITIVE

Controls

Non-LGS generalized epilepsy comparators

Patients with other generalized epilepsies imaged under the same protocol.

Decision criterion

A unifying-mechanism interpretation is supported if a common thalamocortical network is recruited across etiologies and distinguishes LGS from comparators; a purely convergent-label interpretation is favored if the network signature tracks etiology rather than the LGS diagnosis.

Would support

pathophysiology#Diffuse Thalamocortical Network Dysfunction

Show evidence (1 reference)

PMID:24902608 SUPPORT Human Clinical

"We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."

Supports a shared-network view by showing common cerebral networks engaged by the defining discharges across patients, the empirical basis for the convergent-syndrome position.

What circuit generates the tonic seizures and their electrographic correlate, sleep-activated generalized paroxysmal fast activity — the near-specific hallmark of LGS — and why is it activated by non-REM sleep?

KNOWLEDGE GAP OPEN gap_lgs_tonic_seizure_gpfa_circuit_mechanism

Attached to

pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

Generalized paroxysmal fast activity and tonic seizures are the most LGS-specific features, yet the circuit that produces them is poorly resolved. Competing accounts implicate thalamocortical mechanisms, brainstem arousal systems, and a sleep-state gating that selectively activates the discharge in non-REM sleep. Resolving the generator matters directly for neuromodulation targeting (for example centromedian thalamic stimulation) and for understanding why the hallmark seizure type is sleep-activated.

Proposed experiments

Sleep-state localization of the paroxysmal fast activity generator

intracranial seizure-onset localization experiment

exp_lgs_gpfa_generator_localization

Combine intracranial or high-density scalp recordings with sleep staging and thalamic recording where available to localize the onset of paroxysmal fast activity and test whether non-REM sleep gates a thalamocortical or brainstem generator.

Readouts

Fast-activity onset localization by sleep state

pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

electroencephalography

Direction: POSITIVE

Controls

Wake-state recordings

Matched recordings during wakefulness to isolate the sleep-gating effect.

Decision criterion

A generator is supported if paroxysmal fast activity reproducibly arises from a defined thalamocortical or brainstem node under non-REM sleep and not during matched wakefulness.

Would support

pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

Show evidence (1 reference)

PMID:24902608 SUPPORT Human Clinical

"We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."

Identifies the network engaged by paroxysmal fast activity but does not resolve the specific generator or the sleep-state gating, which is the open question.

How much of the cognitive impairment in LGS is driven by ongoing seizures and interictal epileptiform activity (and therefore potentially modifiable by seizure control) versus fixed injury from the underlying etiology?

KNOWLEDGE GAP OPEN gap_lgs_epileptic_encephalopathy_cognition_reversibility

Attached to

pathophysiology#Interictal Epileptiform Activity-Driven Cognitive Impairment pathophysiology#Cognitive Impairment and Developmental Plateau

The developmental and epileptic encephalopathy concept holds that the epileptic activity itself contributes to cognitive decline beyond the underlying cause. If a substantial fraction of the cognitive burden is activity-driven, then earlier and more complete seizure control could improve developmental outcome; if it is fixed etiologic injury, cognitive prognosis would be largely independent of seizure control. Because LGS is typically drug-resistant, this fraction has been very hard to estimate, and it is a central open question with direct therapeutic stakes.

Proposed experiments

Coupling of seizure/EEG burden to cognitive trajectory in LGS

longitudinal cohort coupling experiment

exp_lgs_seizure_control_cognition_coupling

In a prospective LGS cohort, relate quantitative interictal epileptiform burden and seizure frequency to longitudinal neurodevelopmental trajectory, and where an intervention achieves marked seizure reduction, test whether cognitive trajectory inflects independently of etiology.

Readouts

Cognitive trajectory versus epileptiform burden

pathophysiology#Cognitive Impairment and Developmental Plateau

neuropsychological assessment electroencephalography

Direction: POSITIVE

Controls

Etiology-stratified comparison

Stratify by etiology to separate activity-driven from fixed injury effects.

Decision criterion

An activity-driven contribution is supported if reductions in epileptiform burden are followed by improvement or stabilization of cognitive trajectory within etiology strata; a fixed-injury interpretation is favored if trajectory tracks etiology regardless of seizure control.

Would support

pathophysiology#Interictal Epileptiform Activity-Driven Cognitive Impairment

Can any animal model reproduce the convergent LGS electroclinical syndrome (tonic seizures with generalized paroxysmal fast activity plus slow spike-and-wave), or do current single-gene models only capture one etiologic entry point into the syndrome?

HUMAN MODEL MISMATCH OPEN gap_lgs_animal_model_convergent_syndrome_fidelity

Attached to

pathophysiology#Diffuse Thalamocortical Network Dysfunction pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

Because LGS is a convergent syndrome rather than a single-gene disease, a faithful model would need to reproduce the shared network phenotype, not just one causative lesion. Existing models (for example GABRB3 knock-in mice) recapitulate a single genetic etiology and some seizure features, but whether they reproduce the defining tonic-seizure and paroxysmal fast-activity network signature of human LGS is uncertain. This is a translational-validity gap, distinct from an absence of evidence: model data exist, but their fidelity to the convergent human syndrome is the open question.

Proposed experiments

Network-phenotype fidelity testing across LGS etiologic models

cross-model network phenotyping experiment

exp_lgs_model_network_phenotype_fidelity

Phenotype several distinct LGS etiologic models (a GABA-A receptor model, an mTOR/structural model, and a synaptic model) with the same sleep-EEG and network readouts used clinically, testing whether any reproduces tonic seizures with sleep-activated fast activity and slow spike-and-wave.

Readouts

Tonic seizure and fast-activity phenotype

pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

electroencephalography

Direction: POSITIVE

Controls

Wild-type littermates

Matched wild-type animals recorded under identical protocols.

Decision criterion

Human fidelity for a model is supported if it reproduces the sleep-activated paroxysmal fast activity and tonic seizure signature; models that show only isolated seizures without the network signature are flagged as capturing an etiologic entry point rather than the LGS syndrome.

Would support

pathophysiology#Diffuse Thalamocortical Network Dysfunction

Show evidence (1 reference)

PMID:23934111 SUPPORT Human Clinical

"GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."

Identifies GABRB3 as an LGS-associated gene whose mouse models test a single etiology; the mismatch question is whether such single-gene models reproduce the convergent LGS network phenotype.

⚙

Pathophysiology

10

Heterogeneous Etiologic Brain Insult

LGS is not caused by a single lesion. A structurally, genetically, metabolically, or acquired-injury-based insult to the developing brain (e.g., hypoxic-ischemic encephalopathy, cortical malformation, tuberous sclerosis, CNS infection, or a monogenic developmental and epileptic encephalopathy variant) supplies the upstream cause. This node captures the single concept of the initiating brain insult; its diverse specific causes converge downstream on a shared network disorder.

Neuron CL:0000540

Downstream

Age-Dependent Evolution from Infantile Spasms In a subset of children the same insult first manifests as infantile spasms and later transitions to the LGS electroclinical pattern.

Diffuse Thalamocortical Network Dysfunction Regardless of specific cause, the insult produces a diffusely dysfunctional thalamocortical network that generates the LGS phenotype.

Global Developmental Delay The initiating brain insult frequently produces developmental delay that precedes or accompanies seizure onset, separately from the later seizure-driven cognitive plateau.

Show evidence (2 references)

PMID:29124439 SUPPORT Human Clinical

"The etiology of LGS is often divided into two groups: identifiable (genetic-structural-metabolic) in 65 to 75% of the patients and LGS of unknown cause in others."

Quantifies the heterogeneous upstream cause: an identifiable structural, genetic, or metabolic insult is present in roughly two-thirds to three-quarters of patients, with the remainder of unknown cause.

PMID:21275978 SUPPORT Human Clinical

"Even if etiologies of Lennox-Gastaut syndrome (LGS) are diverse, the multiple causes converge into a final common pathway that results in this specific epilepsy phenotype."

States the convergence premise this node encodes: diverse initiating insults funnel into one downstream pathway rather than each producing its own distinct phenotype.

Age-Dependent Evolution from Infantile Spasms

In a substantial subset of patients, LGS emerges from a prior diagnosis of infantile spasms (West syndrome) as the developing brain's epileptic expression shifts with maturation. This node captures the single concept of the age-dependent syndrome transition, a distinctive route into LGS separate from de novo presentation.

Neuron CL:0000540

Downstream

Diffuse Thalamocortical Network Dysfunction The maturational transition consolidates into the diffuse thalamocortical network dysfunction underlying LGS.

Show evidence (4 references)

PMID:10368073 SUPPORT Human Clinical

"Fifty percent of children with IS developed Lennox-Gastaut syndrome (LGS) before age 11 years."

Population-based surveillance quantifies the West-syndrome-to-LGS transition from the infantile-spasms side: half of children with infantile spasms went on to develop LGS in childhood.

PMID:11071139 SUPPORT Human Clinical

"a previous diagnosis of West syndrome (OR 11.6), a symptomatic etiology of epilepsy (OR 9.5), and an early age at onset of epilepsy (OR 4.7)"

Multicentre LGS cohort records prior West syndrome as a recognised route into LGS and an independent risk factor for severe intellectual disability, establishing the transition as a clinically distinct trajectory rather than an incidental association.

PMID:41283772 SUPPORT Human Clinical

"Timely diagnosis and effective treatment of Lennox-Gastaut syndrome (LGS) improve prognosis and lower health care costs, but the transition from infantile epileptic spasms syndrome (IESS) to LGS is highly variable and insidious."

Establishes the IESS-to-LGS transition modeled by this node as a recognized clinical route into the syndrome, and characterizes it as gradual and variable rather than an abrupt switch.

+ 1 more reference

Diffuse Thalamocortical Network Dysfunction

LGS behaves as a secondary network ("secondary generalized") epilepsy in which widespread, bilaterally synchronous epileptic activity is generated by a diffusely dysfunctional thalamocortical network rather than by a single cortical focus. This node captures the single concept of the network-level substrate that unifies the heterogeneous etiologies.

Neuron CL:0000540

Downstream

Cortical Excitation-Inhibition Imbalance Network dysfunction expresses locally as a shift toward excitation over inhibition in cortical circuits.

Show evidence (3 references)

PMID:24902608 SUPPORT Human Clinical

"We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."

Neuroimaging evidence that the characteristic LGS discharges engage a shared cerebral network across etiologies, supporting the secondary network model in which a diffusely dysfunctional network, not a single focus, generates the phenotype.

PMID:21275978 SUPPORT Human Clinical

"Individual and group analyses revealed significant activation of brainstem and thalamus (especially centromedian and anterior thalamus) associated with epileptiform discharges in patients with LGS."

Simultaneous EEG-fMRI in 11 children with LGS localises the discharge-linked network to thalamus (centromedian and anterior nuclei) and brainstem, naming the subcortical half of the thalamocortical substrate; the pattern was absent in the multifocal-epilepsy control children.

PMID:25400619 SUPPORT Human Clinical

"Electroencephalography (EEG) shows characteristic generalized epileptic activity that is similar in those with lesional, genetic, or unknown causes, suggesting a common underlying mechanism."

Systematic review of LGS neuroimaging argues that the electrographic phenotype is etiology-independent, which is the observation that motivates modelling a shared network node downstream of heterogeneous causes.

Cortical Excitation-Inhibition Imbalance

Within the dysfunctional network, the balance between synaptic excitation and GABAergic inhibition is shifted toward excitation, lowering the threshold for hypersynchronous discharges. This node captures the single concept of the excitation-inhibition imbalance and conforms to the shared epilepsy final common pathway.

GABAergic interneuron CL:0000617

Regulation of GABAergic synaptic transmission GO:0032228 ↓ DECREASED

Downstream

Slow Spike-and-Wave Discharge Generation The imbalance supports the corticothalamic oscillation seen as slow spike-and-wave activity.

Generalized Paroxysmal Fast Activity and Tonic Seizure Generation The imbalance also enables the sleep-activated fast-activity discharges that underlie tonic seizures.

Myoclonic Seizures The same lowered threshold for hypersynchronous discharge supports the myoclonic seizures that commonly accompany the defining LGS seizure types. This edge carries no citation on purpose: the general excitation-inhibition principle now sits on the source node, and nothing found establishes what makes this particular network produce myoclonic rather than another seizure type, which is what INDIRECT_UNKNOWN_INTERMEDIATES records.

Generalized Tonic-Clonic Seizures Bilateral tonic-clonic seizures arise when hypersynchronous discharge propagates through the diffusely disinhibited network. This edge carries no citation on purpose, for the same reason as the myoclonic edge above: the review sentence that was cited here is the general excitation-inhibition principle, which now sits on the source node, and it does not distinguish generalized tonic-clonic from any other seizure type.

Show evidence (3 references)

PMID:30764523 SUPPORT INDIRECT Other

"increased excitation, decreased inhibition, or both favor a hyperexcitable state and an increased propensity for seizure generation and epileptogenesis"

States the excitation-inhibition imbalance principle that this node asserts, quoted as the single sentence that carries it. Evidence source is OTHER because this is a review article stating the general theory rather than reporting a measurement, and directness is INDIRECT because the claim is generic to epilepsy rather than measured in LGS. It belongs on the node for that reason and is deliberately not attached to the individual seizure-type edges below - the review says nothing about which seizure type a given network produces.

PMID:26950270 SUPPORT In Vitro

"LGS-associated GABRB3(D120N, E180G, Y302C) mutations located at β+ subunit interfaces reduced whole cell currents by decreasing single channel open probability without loss of surface receptors."

Patch-clamp characterisation of the de novo GABRB3 variants found in LGS probands shows they reduce GABA-A receptor current, giving a direct molecular instance of the loss of GABAergic inhibition this node asserts. The evidence covers the monogenic GABA-A subset of LGS and does not establish the same lesion in structural or unknown-cause cases.

PMID:23934111 SUPPORT Human Clinical

"GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."

Identifies GABRB3, a GABA-A receptor subunit gene, as a genome-wide significant cause in the IS/LGS cohort, linking the inhibitory synapse to LGS at the genetic level.

Slow Spike-and-Wave Discharge Generation

A defining electrographic feature of LGS is the diffuse slow (<2.5 Hz) spike-and-wave complex, reflecting pathological corticothalamic oscillation. This node captures the single concept of slow spike-and-wave generation, the substrate of atypical absence seizures.

Neuron CL:0000540

Downstream

Multiple Drug-Resistant Seizure Types Slow spike-and-wave discharges manifest clinically as atypical absence seizures within the LGS seizure repertoire.

Atypical Absence Seizures The diffuse slow (<2.5 Hz) spike-and-wave discharge is the electrographic correlate of the atypical absence seizures seen clinically.

Nonconvulsive Status Epilepticus Prolonged, near-continuous slow spike-and-wave activity underlies the episodes of nonconvulsive (atypical absence) status epilepticus that recur over the disease course.

Show evidence (4 references)

PMID:20149600 SUPPORT Human Clinical

"EEG showed slow background activity in 21/27 patients, diffuse slow spike-wave discharges (DSSW) during wakefulness in 22/27, and bursts of diffuse fast rhythms (DFR) in sleep in all patients."

Documents diffuse slow spike-wave as the waking interictal signature in 22 of 27 patients, establishing the discharge this node generates as a near-constant feature rather than an occasional finding.

PMID:24902608 SUPPORT Human Clinical

"SSW showed mixed increased and decreased fMRI activity, with preevent increases in association cortex and thalamus, and then prominent postevent reduction."

Event-related EEG-fMRI shows that slow spike-and-wave discharges are preceded by coupled association-cortex and thalamic activation, the corticothalamic signature this node attributes to them.

PMID:38976954 SUPPORT Human Clinical

"Out of 20 studies, only 15 studies mentioned GPFA in 46.6 % patients and SSW in 91.7 % patients."

Systematic review of 1167 patients establishing slow spike-and-wave as the near-universal electrographic finding in LGS (91.7%), supporting its treatment here as a defining generator node rather than an incidental feature.

+ 1 more reference

Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

The second defining electrographic feature is sleep-activated generalized paroxysmal fast activity (GPFA), the correlate of tonic seizures, which are the most characteristic seizure type of LGS and predominate in non-REM sleep. This node captures the single concept of fast-activity/tonic seizure generation.

Neuron CL:0000540

Downstream

Atonic Drop Attack Generation Tonic and related discharges contribute to sudden tone changes producing drop attacks.

Multiple Drug-Resistant Seizure Types Generalized paroxysmal fast activity contributes the tonic component to the multiple co-occurring, treatment-resistant seizure types that define the syndrome. This edge carries no citation on purpose: the drug-resistance quote that was attached here attests a property of the target node, not this source-to-target step, and has been moved onto that node.

Tonic Seizures Sleep-activated generalized paroxysmal fast activity is the electrographic correlate of the tonic seizures that are the most characteristic seizure type of LGS.

Show evidence (4 references)

PMID:25400619 SUPPORT Human Clinical

"Scalp EEG of the tonic seizures of LGS is characterized by a diffuse high-voltage slow transient evolving into generalized low-voltage fast activity, likely reflecting sustained fast neuronal firing over a wide cortical area."

Ties the tonic seizure directly to its fast-activity electrographic correlate and interprets it as sustained firing across a wide cortical area, which is the generation mechanism this node names.

PMID:20149600 SUPPORT Human Clinical

"On the contrary, sleep EEG showed the persistence of DFR in all."

Sleep-recorded diffuse fast rhythms persisted in all 27 adults even after waking slow spike-wave had resolved in most, supporting the non-REM sleep activation of the fast-activity discharge that this node asserts.

PMID:24902608 SUPPORT Human Clinical

"PFA-robust fMRI signal increases were observed in frontal and parietal association cortical areas, thalamus, and pons, with simultaneous increases in both "attention" and resting-state (default mode) networks, a highly unusual pattern."

Maps the generalized paroxysmal fast activity of this node onto a specific cortical-thalamic-pontine network, distinguishing it from the slow spike-and-wave pattern recorded in the same patients.

+ 1 more reference

Atonic Drop Attack Generation

Sudden loss (atonic) or brief increase (tonic) of postural tone produces drop attacks (astatic seizures), a major source of injury in LGS. This node captures the single concept of drop-attack generation, distinct from the tonic and absence seizure mechanisms above.

Neuron CL:0000540

Downstream

Multiple Drug-Resistant Seizure Types Drop attacks are one of the multiple drug-resistant seizure types comprising the syndrome.

Atonic Seizures (Drop Attacks) Sudden loss of postural tone produces the atonic (astatic) drop attacks observed clinically, a major source of falls and injury.

Show evidence (3 references)

PMID:37823366 SUPPORT Human Clinical

"The dominant seizure type was drop attacks (tonic or atonic) in 102 patients."

In a multinational series of 127 children with LGS, drop attacks of either tonic or atonic type dominated the seizure burden, supporting both the prominence of this node and its dual tone-change mechanism.

PMID:40937826 SUPPORT Human Clinical

"drop attacks are rarely pure atonic seizures but are often epileptic spasms or other types of seizures with increased muscle tone"

Video-EEG-electromyography evidence supports the increased-tone half of this node's mechanism but qualifies its atonic framing: pure atonic falls are the exception, and epileptic spasms account for many drop attacks, so the node's name should not be read as a claim that the mechanism is predominantly atonic.

PMID:38976954 SUPPORT Human Clinical

"Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."

Establishes atonic seizures as a recurrent component of the LGS seizure repertoire (34.8% of 1167 pooled patients), substantiating drop-attack generation as a distinct mechanism node rather than an occasional feature.

Interictal Epileptiform Activity-Driven Cognitive Impairment

LGS is a developmental and epileptic encephalopathy: beyond any cognitive effect of the underlying cause, the frequent seizures and near-continuous interictal epileptiform activity are themselves thought to impair cognitive development and drive stagnation or regression. This node captures the single concept of the epileptic-encephalopathy contribution to cognition.

Neuron CL:0000540

Downstream

Cognitive Impairment and Developmental Plateau Ongoing epileptiform activity contributes to the cognitive plateau and regression characteristic of the syndrome.

Epileptic Encephalopathy Frequent seizures together with abundant interictal epileptiform activity constitute the epileptic encephalopathy itself, the clinical designation of this mechanism.

Show evidence (3 references)

PMID:26945476 SUPPORT Human Clinical

"Abnormal interactions were present during fMRI periods with and without discharges, indicating that impaired network behavior may endure during periods without scalp-detectable epileptic activity."

Task-free EEG-fMRI in 15 patients versus 17 controls shows the cognitive networks recruited by LGS discharges are persistently disorganised between discharges, the mechanism by which epileptiform activity could impair cognition beyond the ictal event itself.

PMID:28295228 SUPPORT Human Clinical

"This case illustrates that the epileptic process of LGS can directly contribute to abnormal network organization, and that this network disruption may be reversible."

Pre/post-surgical fMRI in a child whose seizures remitted after resection provides the directional evidence this node needs -- removing the epileptic activity reorganised the cognitive networks -- though as a single case it does not quantify how much of the cognitive burden is activity-driven.

PMID:38976954 SUPPORT INDIRECT Human Clinical

"Longer duration of SSW discharges and disorganized background are associated with poor outcome."

Links the burden of interictal epileptiform activity to worse outcome, consistent with the developmental-and-epileptic-encephalopathy claim that ongoing epileptiform activity itself contributes to the cognitive trajectory. Graded INDIRECT because the association is correlational and cannot separate an activity-driven effect from severity of the underlying etiology, which is the open question recorded in the attached knowledge-gap discussion.

Multiple Drug-Resistant Seizure Types

The clinical hallmark of LGS is the co-occurrence of several seizure types in one child, characteristically tonic, atonic, and atypical absence seizures, that are typically resistant to antiseizure medications. This node captures the single concept of the multiple-drug-resistant-seizure endpoint and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Show evidence (6 references)

PMID:30255934 SUPPORT Human Clinical

"Most LGS patients continued with refractory seizures"

A prospective community-based cohort establishes that the seizures remain drug resistant over long follow-up, which is the defining property this node asserts. Moved here from the incoming causal edge, where the same quote attested this node's property rather than the source-to-target step.

PMID:37212330 SUPPORT Human Clinical

"Most individuals with LGS will require treatment with multiple ASMs."

Review of randomized double-blind placebo-controlled trials in LGS concludes that polypharmacy is the norm, the practical expression of the drug resistance this endpoint node asserts.

PMID:25616450 SUPPORT Human Clinical

"For a mean follow-up duration of 19.3 years (range 8.3-32.5 years), finally sixteen patients (23.5%) were seizure-free."

Quantifies the drug-resistant endpoint: even with ketogenic diet and epilepsy surgery available, fewer than a quarter of 68 patients reached seizure freedom over a mean of 19 years.

+ 3 more references

Cognitive Impairment and Developmental Plateau

Most children with LGS develop intellectual disability with developmental plateau or regression and frequent behavioural problems. This node captures the single concept of the cognitive/developmental outcome, the endpoint of both the underlying etiology and the epileptic encephalopathy.

Neuron CL:0000540

Downstream

Intellectual Disability The developmental plateau or regression is expressed clinically as intellectual disability in most affected children.

Behavioral Abnormalities Hyperactivity, aggression, and autistic features accompany the cognitive outcome and add to the disability burden.

Show evidence (4 references)

PMID:25616450 SUPPORT Human Clinical

"In cognitive terms, 94.7% of patients exhibited moderate to profound mental retardation."

In 68 adults followed a mean of 19.3 years, almost all had moderate to profound intellectual disability, quantifying the cognitive endpoint of this node.

PMID:20149600 SUPPORT Human Clinical

"A moderate to severe cognitive impairment was observed in 26/27 patients."

Independent adult LGS cohort reproduces the near-universal cognitive outcome, in patients aged 40-59 years and therefore decades after onset.

PMID:34798494 SUPPORT Human Clinical

"While intellectual dysfunction may not be evident at the onset of the disease, cognitive impairment usually becomes apparent over time, and almost all patients would suffer from poor social outcomes in their adulthood."

Directly supports the plateau/regression framing of this node: cognition is often unremarkable at onset and deteriorates relative to expectation over the disease course, ending in near-universal poor adult social outcome.

+ 1 more reference

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Tonic Seizures HP:0010818

Show evidence (4 references)

PMID:21790560 SUPPORT Human Clinical

"All patients have tonic seizures during sleep that may be subtle"

Review of the definition and natural history of LGS states that tonic seizures, characteristically sleep-activated, occur in all patients.

PMID:29126048 SUPPORT Human Clinical

"The most prevalent seizure types at follow-up were atypical absences (28/38), tonic (28/38), generalized tonic-clonic (17/38), focal (11/38), and myoclonic seizures (9/38)."

Long-term follow-up of 38 adults with LGS found tonic seizures among the two most prevalent seizure types.

PMID:39700524 SUPPORT Other

"characterized by multiple types of drug-resistant seizures (which must include tonic seizures)"

Expert consensus guidance states that the drug-resistant seizure repertoire of LGS must include tonic seizures, establishing them as the obligate seizure type of the syndrome.

+ 1 more reference

Atonic Seizures (Drop Attacks) HP:0010819

Show evidence (3 references)

PMID:29768152 SUPPORT Human Clinical

"During the 28-day baseline period, the median number of drop seizures was 85 in all trial groups combined."

In a 225-patient LGS trial cohort, drop seizures were frequent enough at baseline to serve as the primary endpoint, with a median of 85 per 28 days.

PMID:29124439 SUPPORT Human Clinical

"Reduction in frequency of the most incapacitating seizures (e.g., drop attacks and tonic-clonic seizures) should be the major objective."

Clinical review identifies drop attacks as one of the most incapacitating seizure types encountered in LGS.

PMID:38976954 SUPPORT Human Clinical

"Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."

Establishes atonic seizures in 34.8% of pooled LGS patients, supporting drop attacks as a core rather than incidental component of the seizure repertoire.

Atypical Absence Seizures HP:0007270

Show evidence (2 references)

PMID:29126048 SUPPORT Human Clinical

"The most prevalent seizure types at follow-up were atypical absences (28/38), tonic (28/38), generalized tonic-clonic (17/38), focal (11/38), and myoclonic seizures (9/38)."

Atypical absences were the most prevalent seizure type at follow-up in this adult LGS cohort, occurring in 28 of 38 patients.

PMID:38976954 SUPPORT Human Clinical

"Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."

Establishes atypical absences as the second most frequent LGS seizure type (44.3% of pooled patients).

Epileptic Encephalopathy HP:0200134

Show evidence (1 reference)

PMID:29124439 SUPPORT Human Clinical

"Lennox-Gastaut syndrome (LGS) is considered an epileptic encephalopathy and is defined by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability."

Review states that LGS is classified as an epileptic encephalopathy, with the defining triad including abundant interictal epileptiform activity.

Intellectual Disability HP:0001249

Show evidence (4 references)

PMID:25616450 SUPPORT Human Clinical

"In cognitive terms, 94.7% of patients exhibited moderate to profound mental retardation."

In a cohort of 68 adults with LGS followed a mean of 19.3 years, nearly all had moderate to profound intellectual disability.

PMID:29126048 SUPPORT Human Clinical

"Besides epilepsy, intellectual disability and behavioral problems were prominent features."

Adult LGS follow-up study reports intellectual disability as a prominent feature alongside the seizures.

PMID:29124439 SUPPORT Human Clinical

"is defined by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability"

Intellectual disability is one of the three defining components of the LGS diagnostic triad.

+ 1 more reference

Myoclonic Seizures HP:0032794

Show evidence (2 references)

PMID:29126048 SUPPORT Human Clinical

"The most prevalent seizure types at follow-up were atypical absences (28/38), tonic (28/38), generalized tonic-clonic (17/38), focal (11/38), and myoclonic seizures (9/38)."

Myoclonic seizures were recorded in 9 of 38 adults with LGS, confirming them as an additional seizure type in the LGS repertoire.

PMID:38976954 SUPPORT Human Clinical

"Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."

Establishes myoclonic seizures in 39.2% of pooled LGS patients, supporting their listing as a common additional seizure type.

Generalized Tonic-Clonic Seizures HP:0002069

Show evidence (2 references)

PMID:29126048 SUPPORT Human Clinical

"The most prevalent seizure types at follow-up were atypical absences (28/38), tonic (28/38), generalized tonic-clonic (17/38), focal (11/38), and myoclonic seizures (9/38)."

Generalized tonic-clonic seizures were present in 17 of 38 adults with LGS at follow-up.

PMID:38976954 SUPPORT Human Clinical

"Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."

Establishes generalized seizures in 38.5% of pooled LGS patients, supporting bilateral tonic-clonic seizures as a common addition to the defining seizure types.

Nonconvulsive Status Epilepticus HP:0031475

Show evidence (2 references)

PMID:11071139 SUPPORT Human Clinical

"Four independent risk factors for severe mental retardation were identified by multivariate analysis. These were in a decreasing order of importance: nonconvulsive status epilepticus (NCSE), odds ratio (OR) 25.2"

Multicentre study of 101 patients with LGS documents nonconvulsive status epilepticus in the cohort and identifies it as the strongest independent risk factor for severe intellectual disability.

PMID:38976954 SUPPORT Human Clinical

"Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."

Reports non-convulsive status epilepticus in 7.0% of pooled LGS patients. This is a cross-sectional figure pooled across EEG studies, so it bounds how often NCSE is captured at a single assessment rather than how often it recurs over the disease course, which is what this phenotype's description claims and what the long-term series cited above speaks to.

Global Developmental Delay HP:0001263

Show evidence (3 references)

PMID:21790560 SUPPORT Human Clinical

"Cognitive stagnation and behavioral problems are seen in almost all patients and lead to a life of dependency."

Review reports developmental stagnation in almost all patients with LGS, the developmental-delay counterpart of the seizure phenotype.

PMID:11071139 SUPPORT Human Clinical

"At the last follow-up, 38% of the patients could not speak, 21% were unable to walk and only 4% were free of seizures."

Long-term follow-up of 101 patients quantifies the global developmental impairment across speech and motor domains.

PMID:33764203 SUPPORT Human Clinical

"Developmental delay and history of seizures prior to the onset of infantile spasms were identified as risk factors for the development of Lennox-Gastaut syndrome (P = .003) as was poor response to first treatment for spasms (P = .004)."

Directly supports the "precedes seizure onset" claim in this phenotype's description: in a 97-child infantile-spasms cohort, developmental delay was a risk factor measured before the LGS diagnosis was made, not merely a later consequence of it.

Behavioral Abnormalities HP:0000708

Show evidence (4 references)

PMID:29126048 SUPPORT Human Clinical

"Besides epilepsy, intellectual disability and behavioral problems were prominent features."

Adult LGS follow-up study reports behavioral problems as a prominent feature of the phenotype.

PMID:21790560 SUPPORT Human Clinical

"Cognitive stagnation and behavioral problems are seen in almost all patients and lead to a life of dependency."

Review reports behavioral problems in almost all patients with LGS and links them to the disability burden.

PMID:39854828 SUPPORT Human Clinical

"characterized by multiple drug-resistant seizure types, specific electroencephalogram (EEG) patterns, and significant cognitive and behavioral impairments"

Review characterizes LGS as involving significant behavioral impairment alongside the seizure and EEG features.

+ 1 more reference

🧬

Genetic Associations

1

Genetically heterogeneous developmental and epileptic encephalopathy genes

Show evidence (2 references)

PMID:23934111 SUPPORT Human Clinical

"de novo mutations in patients with two classical epileptic encephalopathies: infantile spasms (n = 149) and Lennox-Gastaut syndrome (n = 115)."

The Epi4K trio-exome study established that a substantial fraction of LGS is caused by de novo variants, sequencing 115 LGS probands alongside infantile spasms cases.

PMID:23934111 SUPPORT Human Clinical

"GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."

Identifies GABRB3 and ALG13 as genome-wide-significant developmental and epileptic encephalopathy genes in the IS/LGS cohort, illustrating the genetic heterogeneity of LGS.

💊

Medical Actions

5

Broad-Spectrum Antiseizure Medication

Action: Pharmacotherapy NCIT:C15986

Platform: Small molecule

First-line pharmacotherapy uses broad-spectrum antiseizure medications (e.g., valproate, lamotrigine); LGS seizures are typically drug-resistant and require combination therapy. Narrow-spectrum sodium-channel blockers (carbamazepine, oxcarbazepine, phenytoin) and vigabatrin can aggravate atypical absence and myoclonic seizures and are generally avoided.

Show evidence (5 references)

PMID:37212330 SUPPORT Human Clinical

"Valproate continues to be considered the first-line treatment, despite the absence of RDBCTs specifically in LGS."

Review of the LGS trial evidence places valproate first-line while making the strength of that recommendation explicit -- it rests on clinical practice rather than on a randomized double-blind trial in LGS.

PMID:20158289 SUPPORT Human Clinical

"Valproate, lamotrigine and topiramate were considered recently by expert panels in the US and Europe to be the first-line drugs."

Independent expert-panel consensus on both continents names the same broad-spectrum agents as first-line, supporting the composition of this treatment.

PMID:9593229 SUPPORT Human Clinical

"An inappropriate choice of the AED (i.e., a purely pharmacodynamic mechanism) can induce worsening when CBZ or VGB is used in absence and myoclonic seizures."

Supports the avoidance clause in this treatment's description: carbamazepine and vigabatrin aggravate exactly the atypical absence and myoclonic seizure types that form part of the LGS repertoire.

+ 2 more references

LGS-Indicated Adjunctive Antiseizure Agents

Action: Pharmacotherapy NCIT:C15986

Agent: cannabidiol CHEBI:69478 fenfluramine CHEBI:5000 rufinamide CHEBI:134966 clobazam CHEBI:31413

Platform: Small molecule

Eight agents carry a specific FDA indication for LGS-associated seizures: clonazepam, felbamate, lamotrigine, topiramate, rufinamide, clobazam, cannabidiol, and fenfluramine. Note that the regulatory set and the set with randomized double-blind trial support are not the same list - clonazepam is FDA-approved without such a trial, and lamotrigine appears in both the first-line broad-spectrum entry and here.

Show evidence (5 references)

PMID:29768152 SUPPORT Human Clinical

"median percent reduction from baseline in drop-seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group"

Randomized placebo-controlled trial (GWPCARE3) demonstrating that add-on cannabidiol reduces drop-seizure frequency in LGS, supporting its role as an LGS-indicated adjunctive agent.

PMID:37212330 SUPPORT Human Clinical

"Evidence from RDBCTs supports the use of cannabidiol, clobazam, felbamate, fenfluramine, lamotrigine, rufinamide, and topiramate as adjunct treatments for drop seizures."

Names the adjunctive agents with randomized double-blind placebo-controlled trial support in LGS, which is the set this treatment entry lists.

PMID:35499850 SUPPORT Human Clinical

"The trial met its primary efficacy end point: patients in the 0.7-mg/kg/d fenfluramine group achieved a -19.9 percentage points (95% CI, -31.0 to -8.7 percentage points; P = .001) estimated median difference in drop seizures from baseline vs placebo."

Phase 3 randomized placebo-controlled trial in 263 patients establishing adjunctive fenfluramine as effective against drop seizures in LGS.

+ 2 more references

Ketogenic Diet Therapy

Action: ketogenic diet intake Ontology label: Ketogenic Diet NCIT:C173168

Platform: Behavioral / lifestyle

Ketogenic and modified Atkins diets are used for drug-resistant LGS seizures.

Show evidence (6 references)

PMID:22443637 SUPPORT Human Clinical

"after 6 months, 36 (51%) achieved more than 50% seizure reduction, 16 (23%) experienced more than 90% seizure reduction, and 1 (1%) achieved seizure freedom."

Largest single-institution LGS ketogenic-diet series (71 children) with an intent-to-treat analysis: about half responded, quantifying the benefit claimed for this treatment.

PMID:22443637 SUPPORT Human Clinical

"In the literature, 88 of 189 (47%) children with LGS had more than 50% seizure reduction after 3 to 36 months of ketogenic diet treatment."

Pooled literature figure reproduces the same response rate outside the reporting institution, so the estimate is not single-centre.

PMID:25616450 SUPPORT Human Clinical

"The KD was administered to 19 patients, five patients maintained a seizure free state during the KD but only one patient was able to maintain a seizure free state by continuing on a modified Atkins diet."

Supports short-term efficacy while qualifying durability: seizure freedom achieved on the ketogenic diet was largely not maintained on a modified Atkins diet in long-term follow-up.

+ 3 more references

Corpus Callosotomy

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Platform: Surgery

Palliative corpus callosotomy is used to reduce drop attacks (tonic/atonic seizures) refractory to medication.

Show evidence (5 references)

PMID:37823366 SUPPORT Human Clinical

"Overall, there was at least a 50% reduction in drop attacks and other seizures in 83% and 60%, respectively."

In 127 children with LGS whose vagus nerve stimulation had failed, callosotomy halved drop attacks in 83%, supporting the palliative drop-attack indication this treatment states.

PMID:37823366 SUPPORT Human Clinical

"Permanent morbidity occurred in 1.5%, with no mortality."

Quantifies the surgical risk that makes this a viable palliative option in the same multinational series.

PMID:40937826 SUPPORT Human Clinical

"Recent studies suggest that epileptic spasms are cortically or hemispherically generated seizures and that disconnecting the corpus callosum potentially interrupts bilaterally synchronous seizure activities, supporting the rationale for surgery in patients with epileptic drop attacks."

States the mechanistic rationale linking callosal disconnection to the bilaterally synchronous discharge that produces drop attacks.

+ 2 more references

Vagus Nerve Stimulation

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Platform: Device

Vagus nerve stimulation is a palliative neuromodulation option for drug-resistant LGS.

Show evidence (5 references)

PMID:33188523 SUPPORT Human Clinical

"A random-effects model produced a pooled proportion of 54% (95% confidence intervals [CI]: 45%, 64%) of patients with LGS who responded to adjunctive VNS Therapy"

Meta-analysis of 17 studies and 480 patients gives the pooled responder rate for adjunctive vagus nerve stimulation in LGS.

PMID:33188523 SUPPORT Human Clinical

"Per an exploratory analysis, the calculated incidence of serious adverse events associated with VNS Therapy was 9% (95% CI: 5%, 14%)"

Records the adverse-event burden alongside the response rate; the authors attribute the higher-than-expected rate to inconsistent definitions across the pooled studies rather than to a distinct hazard in LGS.

PMID:37823366 SUPPORT Human Clinical

"Although CC is more effective than VNS as the primary neurosurgical treatment for LGS-associated drop attacks, there are limited data regarding the added value of CC following VNS."

Positions vagus nerve stimulation against corpus callosotomy for the drop-attack indication: it is the less effective of the two palliative options, which qualifies rather than contradicts its use here.

+ 2 more references

📈

Progression

3

Onset

Age: 1-8 years, peak 3-5 years

LGS begins in early childhood, typically between ages 1 and 8 with a peak at 3-5 years. In a subset the syndrome is preceded by infantile spasms.

Show evidence (2 references)

PMID:21790560 SUPPORT Human Clinical

"Lennox-Gastaut syndrome (LGS) is a rare epileptic encephalopathy with a peak age of onset of 3-5 years of age."

Establishes the peak age of onset for the syndrome.

PMID:10368073 SUPPORT Human Clinical

"Fifty percent of children with IS developed Lennox-Gastaut syndrome (LGS) before age 11 years."

Places the West-syndrome-to-LGS transition inside the childhood onset window for the subset of patients who arrive at LGS that way.

Established childhood epileptic encephalopathy

Age: Childhood to adolescence

Multiple seizure types coexist and are drug-resistant, and cognitive development stagnates or regresses. Recurrent nonconvulsive status epilepticus during this phase is the strongest independent predictor of severe intellectual disability.

Show evidence (2 references)

PMID:21790560 SUPPORT Human Clinical

"Cognitive stagnation and behavioral problems are seen in almost all patients and lead to a life of dependency."

Describes the developmental course during the established phase.

PMID:11071139 SUPPORT Human Clinical

"Four independent risk factors for severe mental retardation were identified by multivariate analysis. These were in a decreasing order of importance: nonconvulsive status epilepticus (NCSE), odds ratio (OR) 25.2"

Identifies the event during this phase that carries the greatest independent risk of severe intellectual disability.

Adult persistence

Age: Adulthood

Seizures persist into adult life in most patients. Waking EEG may normalize while sleep-recorded fast rhythms and sleep tonic seizures persist, so a standard waking EEG can be misleading in adults. Seizure freedom is reached by a minority even with diet and surgical options.

Show evidence (3 references)

PMID:20149600 SUPPORT Human Clinical

"At last observation, 11 patients only had TS during wakefulness, but all still presented TS during sleep; AA persisted in 6 patients."

Shows the adult evolution of the seizure repertoire: waking tonic seizures and atypical absences decline while sleep tonic seizures persist in all.

PMID:20149600 SUPPORT Human Clinical

"In adult LGS patients TS during sleep remain the major seizure type; moreover, a standard waking EEG may be normal."

Records the diagnostic consequence of that evolution for adults.

PMID:25616450 SUPPORT Human Clinical

"Only 39.7% of patients had intact independent daily living skills, and 25.4% could not walk, even with support."

Quantifies the adult functional outcome after a mean 19.3 years of follow-up.

📊

Prevalence

1

Children younger than 16 years, Wellington region, New Zealand

Lifetime Prevalence 13.2 per 100,000 (4.1–41.9) 1–9 per 10,000

Population-based cumulative incidence through age 16, ascertained from EEG records across a defined region and syndrome-classified on medical-record and EEG review. Recorded here as a lifetime measure because it counts children affected at any point up to age 16 rather than at a single time point; the confidence interval is wide because LGS is a small subgroup of the ascertained cohort.

Show evidence (1 reference)

PMID:36581463 SUPPORT Human Clinical

"Lennox-Gastaut syndrome 13.2 (95% CI 4.1-41.9)"

Reports the population-based cumulative incidence per 100,000 children for LGS specifically, alongside the other developmental and epileptic encephalopathy syndromes.

🌍

Epidemiology

2

🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Lennox-Gastaut Syndrome:

Atypical benign partial epilepsy (pseudo-Lennox syndrome)

Overlapping Features Pseudo-Lennox syndrome produces generalized minor seizures (atonic-astatic, myoclonic, atypical absence) with sleep-activated focal sharp waves, and is the classic misdiagnosis for LGS in a child with drop attacks.

Distinguishing Features

Tonic seizures and bursts of generalized fast rhythms -- the two features most specific to LGS -- are absent in pseudo-Lennox syndrome.
The interictal EEG shows Rolandic-type focal sharp and slow waves that generalize in sleep, rather than the diffuse slow spike-and-wave of LGS.
The prognosis diverges: clinical remission is the rule in pseudo-Lennox syndrome, whereas LGS epilepsy is typically lifelong.

Show evidence (3 references)

PMID:11315196 SUPPORT Human Clinical

"No tonic seizures and no fast spike series (bursts of 10-20 Hz rhythms) were observed."

In 43 children with atypical benign partial epilepsy, the two most LGS-specific features were absent, which is the discriminating observation.

PMID:11315196 SUPPORT Human Clinical

"At last follow-up, 84% of patients were in clinical remission. All subjects older than age 15 were seizure-free."

The prognostic divergence from LGS, in which seizures are typically lifelong and seizure freedom is reached by a minority.

PMID:21790560 SUPPORT Human Clinical

"The differential diagnosis includes other symptomatic generalized epilepsies and pseudo-Lennox syndrome. Misdiagnosis is common."

Names pseudo-Lennox syndrome as the differential and records that misdiagnosis is frequent, which is why this entry is listed.

🔬

Clinical Trials

2

NCT02224560 PHASE_III COMPLETED

GWPCARE3: randomized, double-blind, placebo-controlled phase 3 trial of adjunctive cannabidiol (10 and 20 mg/kg/day) for drop seizures in children and adults with Lennox-Gastaut syndrome, reported in PMID:29768152.

Target Phenotypes: Atonic seizure HP:0010819 Generalized tonic seizure HP:0010818

Show evidence (2 references)

clinicaltrials:NCT02224560 SUPPORT Other

"The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS)."

ClinicalTrials.gov registration record establishing the trial's identity, LGS population, and drop-seizure primary endpoint.

PMID:29768152 SUPPORT Human Clinical

"median percent reduction from baseline in drop-seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group"

Reports the trial's primary-endpoint result for the higher cannabidiol dose.

NCT03355209 PHASE_III COMPLETED

Two-part phase 3 study of fenfluramine (ZX008) as adjunctive therapy for seizures in children and adults with Lennox-Gastaut syndrome: a randomized, double-blind, placebo-controlled trial of two fixed doses followed by an open-label extension. Reported in PMID:35499850.

Target Phenotypes: Atonic seizure HP:0010819 Generalized tonic-clonic seizure HP:0002069

Show evidence (2 references)

clinicaltrials:NCT03355209 SUPPORT Other

"This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS)."

ClinicalTrials.gov registration record establishing the trial's design and LGS population.

PMID:35499850 SUPPORT Human Clinical

"More patients in the 0.7-mg/kg/d fenfluramine group achieved a 50% or greater response (22 of 87 [25%]; P = .02) vs placebo (9 of 87 [10%])."

Reports the responder-rate result of the randomized phase of this trial.

{ }

Source YAML

click to show

name: Lennox-Gastaut Syndrome
creation_date: "2026-07-17T00:00:00Z"
category: Complex
description: >-
  Lennox-Gastaut syndrome (LGS) is a severe childhood-onset developmental and
  epileptic encephalopathy defined by a triad of multiple drug-resistant seizure
  types (notably tonic seizures, atonic/drop attacks, and atypical absences), a
  characteristic interictal EEG showing diffuse slow (<2.5 Hz) spike-and-wave
  complexes together with sleep-activated generalized paroxysmal fast activity,
  and cognitive impairment with behavioural problems. Onset is typically between
  ages 1 and 8 years (peak 3-5). LGS is etiologically heterogeneous: roughly
  two-thirds of cases are symptomatic of an identifiable structural, genetic,
  metabolic, or acquired brain insult, a substantial subset evolves from
  infantile spasms (West syndrome), and the remainder are of unknown cause. It
  is best understood as a shared, age-dependent electroclinical final common
  pathway of diffuse thalamocortical network dysfunction rather than a single
  disease with a single mechanism.
parents:
- Epilepsy
- Neurodevelopmental Disorder
- Neurological Disease
synonyms:
- LGS
- Lennox syndrome
- Epileptic encephalopathy with diffuse slow spike-and-wave
disease_term:
  preferred_term: Lennox-Gastaut syndrome
  term:
    id: MONDO:0016532
    label: Lennox-Gastaut syndrome
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:G40.81
      label: Lennox-Gastaut syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO:0016532
    mapping_justification: >-
      MONDO:0016532 carries ICD10CM:G40.81 as a cross-reference, and the ICD-10-CM
      code is a named Lennox-Gastaut syndrome rubric (its G40.811-G40.814
      children only add intractability and status-epilepticus qualifiers).
    consistency:
    - reference: MONDO:0016532
      consistent: CONSISTENT
      notes: "xref: ICD10CM:G40.81"
  icd11f_mappings:
  - term:
      id: icd11f:651135242
      label: Lennox-Gastaut syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO:0016532
    mapping_justification: >-
      MONDO:0016532 carries icd11.foundation:651135242 as a cross-reference; the
      ICD-11 Foundation entity label is identical to the MONDO label.
    consistency:
    - reference: MONDO:0016532
      consistent: CONSISTENT
      notes: "xref: icd11.foundation:651135242"
  mondo_mappings:
  - term:
      id: MONDO:0016532
      label: Lennox-Gastaut syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0016532 is the current Lennox-Gastaut syndrome disease concept.
  ncit_mappings:
  - term:
      id: NCIT:C84816
      label: Lennox-Gastaut Syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO:0016532
    mapping_justification: >-
      MONDO:0016532 carries NCIT:C84816 as a cross-reference; the NCI Thesaurus
      concept names the same syndrome.
    consistency:
    - reference: MONDO:0016532
      consistent: CONSISTENT
      notes: "xref: NCIT:C84816"
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:35503717
      reference_title: "International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "(3) developmental and/or epileptic encephalopathies, comprising five syndromes: epilepsy with myoclonic-atonic seizures, Lennox-Gastaut syndrome, developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep, hemiconvulsion-hemiplegia-epilepsy syndrome, and febrile infection-related epilepsy syndrome"
      explanation: >-
        The ILAE Task Force on Nosology and Definitions classifies
        Lennox-Gastaut syndrome as a childhood-onset developmental and/or
        epileptic encephalopathy, an epilepsy nosology whose clinical home is
        the neurologic Part.
    notes: >-
      Only Part assigned. LGS is etiologically heterogeneous - structural,
      genetic, metabolic, and acquired insults all converge on the same
      electroclinical syndrome - so a GENETICS_ENVIRONMENT_DISEASE Part would
      overstate the genetic axis for the syndrome as a whole.
prevalence:
- population: Children younger than 16 years, Wellington region, New Zealand
  measure_type: LIFETIME_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 13.2
  rate_low: 4.1
  rate_high: 41.9
  notes: >-
    Population-based cumulative incidence through age 16, ascertained from EEG
    records across a defined region and syndrome-classified on medical-record
    and EEG review. Recorded here as a lifetime measure because it counts
    children affected at any point up to age 16 rather than at a single time
    point; the confidence interval is wide because LGS is a small subgroup of
    the ascertained cohort.
  evidence:
  - reference: PMID:36581463
    reference_title: Epidemiology of Developmental and Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lennox-Gastaut syndrome 13.2 (95% CI 4.1-41.9)"
    explanation: >-
      Reports the population-based cumulative incidence per 100,000 children for
      LGS specifically, alongside the other developmental and epileptic
      encephalopathy syndromes.
epidemiology:
- name: Share of childhood epilepsy
  description: >-
    LGS accounts for a small share of childhood epilepsy, but the published
    figures span an order of magnitude: 1% to 10% of all childhood epilepsies.
    The bounds here are that full reported range rather than any single study's
    estimate; 3% is a commonly cited point value inside it. Camfield attributes
    the spread to how widely prevalence rates vary between reports, and
    differing case definitions and ascertainment are the usual explanation
    rather than genuinely different populations. This is a proportion of
    children who already have epilepsy, not a population prevalence, and must
    not be compared with the rate under `prevalence`.
  minimum_value: 1.0
  maximum_value: 10.0
  unit: percent of childhood epilepsies
  evidence:
  - reference: PMID:20158289
    reference_title: Medical management of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lennox-Gastaut syndrome occurs in 3% of children with epilepsy"
    explanation: >-
      Gives a commonly cited point estimate for the share of childhood epilepsy
      accounted for by LGS, sitting inside the wider reported range.
  - reference: PMID:21790560
    reference_title: Definition and natural history of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reported prevalence rates for LGS vary widely from 1-10% of all childhood epilepsies. Incidence rates are much lower."
    explanation: >-
      Supplies both bounds recorded here, and separates this prevalence-style
      share from the much lower incidence.
- name: Share of all epilepsy
  description: >-
    Among patients with epilepsy of any age, LGS accounts for an estimated 1-2%.
    As above, the denominator is the epilepsy population rather than the general
    population.
  minimum_value: 1.0
  maximum_value: 2.0
  unit: percent of all patients with epilepsy
  evidence:
  - reference: PMID:29124439
    reference_title: "Lennox-Gastaut syndrome: a comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of LGS is estimated between 1 and 2% of all patients with epilepsy."
    explanation: >-
      Gives the share of the whole epilepsy population accounted for by LGS.
progression:
- phase: Onset
  age_range: 1-8 years, peak 3-5 years
  notes: >-
    LGS begins in early childhood, typically between ages 1 and 8 with a peak at
    3-5 years. In a subset the syndrome is preceded by infantile spasms.
  evidence:
  - reference: PMID:21790560
    reference_title: Definition and natural history of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lennox-Gastaut syndrome (LGS) is a rare epileptic encephalopathy with a peak age of onset of 3-5 years of age."
    explanation: >-
      Establishes the peak age of onset for the syndrome.
  - reference: PMID:10368073
    reference_title: The descriptive epidemiology of infantile spasms among Atlanta children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fifty percent of children with IS developed Lennox-Gastaut syndrome (LGS) before age 11 years."
    explanation: >-
      Places the West-syndrome-to-LGS transition inside the childhood onset
      window for the subset of patients who arrive at LGS that way.
- phase: Established childhood epileptic encephalopathy
  age_range: Childhood to adolescence
  notes: >-
    Multiple seizure types coexist and are drug-resistant, and cognitive
    development stagnates or regresses. Recurrent nonconvulsive status
    epilepticus during this phase is the strongest independent predictor of
    severe intellectual disability.
  evidence:
  - reference: PMID:21790560
    reference_title: Definition and natural history of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cognitive stagnation and behavioral problems are seen in almost all patients and lead to a life of dependency."
    explanation: >-
      Describes the developmental course during the established phase.
  - reference: PMID:11071139
    reference_title: "Nonconvulsive status epilepticus--a possible cause of mental retardation in patients with Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four independent risk factors for severe mental retardation were identified by multivariate analysis. These were in a decreasing order of importance: nonconvulsive status epilepticus (NCSE), odds ratio (OR) 25.2"
    explanation: >-
      Identifies the event during this phase that carries the greatest
      independent risk of severe intellectual disability.
- phase: Adult persistence
  age_range: Adulthood
  notes: >-
    Seizures persist into adult life in most patients. Waking EEG may normalize
    while sleep-recorded fast rhythms and sleep tonic seizures persist, so a
    standard waking EEG can be misleading in adults. Seizure freedom is reached
    by a minority even with diet and surgical options.
  evidence:
  - reference: PMID:20149600
    reference_title: "Lennox-Gastaut syndrome in adulthood: clinical and EEG features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At last observation, 11 patients only had TS during wakefulness, but all still presented TS during sleep; AA persisted in 6 patients."
    explanation: >-
      Shows the adult evolution of the seizure repertoire: waking tonic seizures
      and atypical absences decline while sleep tonic seizures persist in all.
  - reference: PMID:20149600
    reference_title: "Lennox-Gastaut syndrome in adulthood: clinical and EEG features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In adult LGS patients TS during sleep remain the major seizure type; moreover, a standard waking EEG may be normal."
    explanation: >-
      Records the diagnostic consequence of that evolution for adults.
  - reference: PMID:25616450
    reference_title: Long-term prognosis of patients with Lennox--Gastaut syndrome in recent decades.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Only 39.7% of patients had intact independent daily living skills, and 25.4% could not walk, even with support."
    explanation: >-
      Quantifies the adult functional outcome after a mean 19.3 years of
      follow-up.
pathophysiology:
- name: Heterogeneous Etiologic Brain Insult
  description: >-
    LGS is not caused by a single lesion. A structurally, genetically,
    metabolically, or acquired-injury-based insult to the developing brain
    (e.g., hypoxic-ischemic encephalopathy, cortical malformation, tuberous
    sclerosis, CNS infection, or a monogenic developmental and epileptic
    encephalopathy variant) supplies the upstream cause. This node captures the
    single concept of the initiating brain insult; its diverse specific causes
    converge downstream on a shared network disorder.
  role: trigger
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:29124439
    reference_title: "Lennox-Gastaut syndrome: a comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The etiology of LGS is often divided into two groups: identifiable (genetic-structural-metabolic) in 65 to 75% of the patients and LGS of unknown cause in others."
    explanation: >-
      Quantifies the heterogeneous upstream cause: an identifiable structural,
      genetic, or metabolic insult is present in roughly two-thirds to
      three-quarters of patients, with the remainder of unknown cause.
  - reference: PMID:21275978
    reference_title: EEG-fMRI reveals activation of brainstem and thalamus in patients with Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Even if etiologies of Lennox-Gastaut syndrome (LGS) are diverse, the multiple causes converge into a final common pathway that results in this specific epilepsy phenotype."
    explanation: >-
      States the convergence premise this node encodes: diverse initiating
      insults funnel into one downstream pathway rather than each producing its
      own distinct phenotype.
  downstream:
  - target: Age-Dependent Evolution from Infantile Spasms
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      In a subset of children the same insult first manifests as infantile
      spasms and later transitions to the LGS electroclinical pattern.
    evidence:
    - reference: PMID:30255934
      reference_title: "Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Children who developed LGS after their initial presentation were first diagnosed with infantile spasms (N=6)"
      explanation: >-
        In a prospective community cohort, infantile spasms was the single most
        common initial presentation among children who later evolved to LGS,
        which is the route this edge describes.
  - target: Diffuse Thalamocortical Network Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Regardless of specific cause, the insult produces a diffusely dysfunctional
      thalamocortical network that generates the LGS phenotype.
    evidence:
    - reference: PMID:28346953
      reference_title: "Lennox-Gastaut Syndrome: A State of the Art Review."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "These dysfunctions are produced by different disorders including hypoxic-ischemic encephalopathies, meningoencephalitis, cortical malformations, neurocutaneous disorders, or tumors."
      explanation: >-
        States the convergence this edge asserts: structurally and etiologically
        unrelated insults all produce the same cortical-subcortical network
        dysfunction. Evidence source is OTHER because this is a review article.
    - reference: PMID:24902608
      reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Seizure freedom in the subjects who proceeded to lesionectomy suggests that cortical lesions are able to establish and maintain this abnormal unstable network behavior."
      explanation: >-
        The lesionectomy result is what makes this edge causal rather than
        associative: removing the initiating lesion resolves the network
        behaviour it had established.
  - target: Global Developmental Delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The initiating brain insult frequently produces developmental delay that
      precedes or accompanies seizure onset, separately from the later
      seizure-driven cognitive plateau.
- name: Age-Dependent Evolution from Infantile Spasms
  description: >-
    In a substantial subset of patients, LGS emerges from a prior
    diagnosis of infantile spasms (West syndrome) as the developing brain's
    epileptic expression shifts with maturation. This node captures the single
    concept of the age-dependent syndrome transition, a distinctive route into
    LGS separate from de novo presentation.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:10368073
    reference_title: The descriptive epidemiology of infantile spasms among Atlanta children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fifty percent of children with IS developed Lennox-Gastaut syndrome (LGS) before age 11 years."
    explanation: >-
      Population-based surveillance quantifies the West-syndrome-to-LGS
      transition from the infantile-spasms side: half of children with
      infantile spasms went on to develop LGS in childhood.
  - reference: PMID:11071139
    reference_title: "Nonconvulsive status epilepticus--a possible cause of mental retardation in patients with Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a previous diagnosis of West syndrome (OR 11.6), a symptomatic etiology of epilepsy (OR 9.5), and an early age at onset of epilepsy (OR 4.7)"
    explanation: >-
      Multicentre LGS cohort records prior West syndrome as a recognised route
      into LGS and an independent risk factor for severe intellectual
      disability, establishing the transition as a clinically distinct
      trajectory rather than an incidental association.
  - reference: PMID:41283772
    reference_title: "EEG functional connectivity as a marker of evolution from infantile epileptic spasms syndrome to Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Timely diagnosis and effective treatment of Lennox-Gastaut syndrome (LGS) improve prognosis and lower health care costs, but the transition from infantile epileptic spasms syndrome (IESS) to LGS is highly variable and insidious."
    explanation: >-
      Establishes the IESS-to-LGS transition modeled by this node as a recognized
      clinical route into the syndrome, and characterizes it as gradual and
      variable rather than an abrupt switch.
  - reference: PMID:41283772
    reference_title: "EEG functional connectivity as a marker of evolution from infantile epileptic spasms syndrome to Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all subjects, connectivity strength was higher at the time of LGS diagnosis than at the preceding timepoint."
    explanation: >-
      Longitudinal EEG in children followed from IESS to LGS shows a consistent
      rise in network connectivity strength across the transition, giving the
      maturational shift a measurable network correlate that links this node to
      the downstream thalamocortical network dysfunction.
  downstream:
  - target: Diffuse Thalamocortical Network Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The maturational transition consolidates into the diffuse thalamocortical
      network dysfunction underlying LGS.
    evidence:
    - reference: PMID:30255934
      reference_title: "Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "there is a link between these two syndromes as some children with WS/IS subsequently develop LGS"
      explanation: >-
        Establishes the syndrome transition itself - West syndrome/infantile
        spasms giving way to the LGS electroclinical state - which is what this
        edge asserts.
- name: Diffuse Thalamocortical Network Dysfunction
  description: >-
    LGS behaves as a secondary network ("secondary generalized") epilepsy in
    which widespread, bilaterally synchronous epileptic activity is generated by
    a diffusely dysfunctional thalamocortical network rather than by a single
    cortical focus. This node captures the single concept of the network-level
    substrate that unifies the heterogeneous etiologies.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:24902608
    reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."
    explanation: >-
      Neuroimaging evidence that the characteristic LGS discharges engage a
      shared cerebral network across etiologies, supporting the secondary
      network model in which a diffusely dysfunctional network, not a single
      focus, generates the phenotype.
  - reference: PMID:21275978
    reference_title: EEG-fMRI reveals activation of brainstem and thalamus in patients with Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individual and group analyses revealed significant activation of brainstem and thalamus (especially centromedian and anterior thalamus) associated with epileptiform discharges in patients with LGS."
    explanation: >-
      Simultaneous EEG-fMRI in 11 children with LGS localises the discharge-linked
      network to thalamus (centromedian and anterior nuclei) and brainstem,
      naming the subcortical half of the thalamocortical substrate; the pattern
      was absent in the multifocal-epilepsy control children.
  - reference: PMID:25400619
    reference_title: Conceptualizing lennox-gastaut syndrome as a secondary network epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Electroencephalography (EEG) shows characteristic generalized epileptic activity that is similar in those with lesional, genetic, or unknown causes, suggesting a common underlying mechanism.'
    explanation: >-
      Systematic review of LGS neuroimaging argues that the electrographic
      phenotype is etiology-independent, which is the observation that motivates
      modelling a shared network node downstream of heterogeneous causes.
  downstream:
  - target: Cortical Excitation-Inhibition Imbalance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Network dysfunction expresses locally as a shift toward excitation over
      inhibition in cortical circuits.
    evidence:
    - reference: PMID:24902608
      reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "We conceptualize Lennox-Gastaut phenotype as a being a network epilepsy, where key cerebral networks become autonomously unstable."
      explanation: >-
        Supports the network becoming autonomously unstable, the network-level
        description of a lowered discharge threshold. Supports this edge only
        through that inference step: EEG-fMRI localizes the instability but does
        not itself measure the excitatory/inhibitory balance, which is why the
        link is annotated INDIRECT_KNOWN_INTERMEDIATES.
- name: Cortical Excitation-Inhibition Imbalance
  description: >-
    Within the dysfunctional network, the balance between synaptic excitation
    and GABAergic inhibition is shifted toward excitation, lowering the threshold
    for hypersynchronous discharges. This node captures the single concept of
    the excitation-inhibition imbalance and conforms to the shared epilepsy
    final common pathway.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  cell_types:
  - preferred_term: GABAergic interneuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: Regulation of GABAergic synaptic transmission
    term:
      id: GO:0032228
      label: regulation of synaptic transmission, GABAergic
    modifier: DECREASED
  evidence:
  - reference: PMID:30764523
    reference_title: "Pediatric Epilepsy Mechanisms: Expanding the Paradigm of Excitation/Inhibition Imbalance."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "increased excitation, decreased inhibition, or both favor a hyperexcitable state and an increased propensity for seizure generation and epileptogenesis"
    explanation: >-
      States the excitation-inhibition imbalance principle that this node
      asserts, quoted as the single sentence that carries it. Evidence source is
      OTHER because this is a review article stating the general theory rather
      than reporting a measurement, and directness is INDIRECT because the claim
      is generic to epilepsy rather than measured in LGS. It belongs on the node
      for that reason and is deliberately not attached to the individual
      seizure-type edges below - the review says nothing about which seizure type
      a given network produces.
  - reference: PMID:26950270
    reference_title: Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "LGS-associated GABRB3(D120N, E180G, Y302C) mutations located at β+ subunit interfaces reduced whole cell currents by decreasing single channel open probability without loss of surface receptors."
    explanation: >-
      Patch-clamp characterisation of the de novo GABRB3 variants found in LGS
      probands shows they reduce GABA-A receptor current, giving a direct
      molecular instance of the loss of GABAergic inhibition this node asserts.
      The evidence covers the monogenic GABA-A subset of LGS and does not
      establish the same lesion in structural or unknown-cause cases.
  - reference: PMID:23934111
    reference_title: "De novo mutations in epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."
    explanation: >-
      Identifies GABRB3, a GABA-A receptor subunit gene, as a genome-wide
      significant cause in the IS/LGS cohort, linking the inhibitory synapse to
      LGS at the genetic level.
  downstream:
  - target: Slow Spike-and-Wave Discharge Generation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The imbalance supports the corticothalamic oscillation seen as slow
      spike-and-wave activity.
    evidence:
    - reference: PMID:24902608
      reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "SSW showed mixed increased and decreased fMRI activity, with preevent increases in association cortex and thalamus, and then prominent postevent reduction."
      explanation: >-
        EEG-fMRI shows slow spike-and-wave events being generated by a
        corticothalamic circuit, with activity rising in association cortex and
        thalamus before each discharge.
  - target: Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The imbalance also enables the sleep-activated fast-activity discharges
      that underlie tonic seizures.
    evidence:
    - reference: PMID:24902608
      reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PFA-robust fMRI signal increases were observed in frontal and parietal association cortical areas, thalamus, and pons"
      explanation: >-
        EEG-fMRI localizes generalized paroxysmal fast activity to a distinct
        cortical-thalamic-brainstem substrate, separating this arm of the
        pathograph from the slow spike-and-wave arm.
  - target: Myoclonic Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The same lowered threshold for hypersynchronous discharge supports the
      myoclonic seizures that commonly accompany the defining LGS seizure types.
      This edge carries no citation on purpose: the general excitation-inhibition
      principle now sits on the source node, and nothing found establishes what
      makes this particular network produce myoclonic rather than another seizure
      type, which is what INDIRECT_UNKNOWN_INTERMEDIATES records.
  - target: Generalized Tonic-Clonic Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Bilateral tonic-clonic seizures arise when hypersynchronous discharge
      propagates through the diffusely disinhibited network. This edge carries no
      citation on purpose, for the same reason as the myoclonic edge above: the
      review sentence that was cited here is the general excitation-inhibition
      principle, which now sits on the source node, and it does not distinguish
      generalized tonic-clonic from any other seizure type.
- name: Slow Spike-and-Wave Discharge Generation
  description: >-
    A defining electrographic feature of LGS is the diffuse slow (<2.5 Hz)
    spike-and-wave complex, reflecting pathological corticothalamic oscillation.
    This node captures the single concept of slow spike-and-wave generation, the
    substrate of atypical absence seizures.
  role: central_effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:20149600
    reference_title: "Lennox-Gastaut syndrome in adulthood: clinical and EEG features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EEG showed slow background activity in 21/27 patients, diffuse slow spike-wave discharges (DSSW) during wakefulness in 22/27, and bursts of diffuse fast rhythms (DFR) in sleep in all patients."
    explanation: >-
      Documents diffuse slow spike-wave as the waking interictal signature in
      22 of 27 patients, establishing the discharge this node generates as a
      near-constant feature rather than an occasional finding.
  - reference: PMID:24902608
    reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SSW showed mixed increased and decreased fMRI activity, with preevent increases in association cortex and thalamus, and then prominent postevent reduction."
    explanation: >-
      Event-related EEG-fMRI shows that slow spike-and-wave discharges are
      preceded by coupled association-cortex and thalamic activation, the
      corticothalamic signature this node attributes to them.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Out of 20 studies, only 15 studies mentioned GPFA in 46.6 % patients and SSW in 91.7 % patients."
    explanation: >-
      Systematic review of 1167 patients establishing slow spike-and-wave as the
      near-universal electrographic finding in LGS (91.7%), supporting its
      treatment here as a defining generator node rather than an incidental
      feature.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Combination of atonic, tonic, and atypical absence seizures correlated with SSW, and myoclonic seizures correlated with GPFA."
    explanation: >-
      Ties slow spike-and-wave to the atypical absence seizures this node feeds
      downstream. The review also correlates SSW with atonic and tonic seizures,
      and myoclonic seizures with GPFA, which does not match the
      generator-to-seizure assignment modeled here; see this node's notes.
  notes: >-
    This entry assigns tonic and atonic seizures downstream of generalized
    paroxysmal fast activity, and atypical absence seizures downstream of slow
    spike-and-wave, following the ictal-correlate literature in which GPFA is
    the ictal signature of the tonic seizure. PMID:38976954 reports something
    different in kind: correlations pooled across studies, in which atonic,
    tonic and atypical absence seizures all correlate with SSW while myoclonic
    seizures correlate with GPFA. For the three seizure types where the two
    differ, that is close to the inverse of what is modeled here.

    The edge set is left unchanged. A pooled cross-study correlation with an
    interictal pattern is weaker warrant for a generator assignment than the
    ictal recordings the current edges rest on, and the review does not claim
    the correlates are seizure-type-specific. Recorded here so the next curator
    does not have to re-derive the discrepancy, and so that revisiting it is a
    deliberate decision rather than an accident.
  downstream:
  - target: Multiple Drug-Resistant Seizure Types
    causal_link_type: DIRECT
    description: >-
      Slow spike-and-wave discharges manifest clinically as atypical absence
      seizures within the LGS seizure repertoire.
    evidence:
    - reference: PMID:34798494
      reference_title: "Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "multiple seizure types, characteristic electroencephalographic patterns [either bursts of slow spike-waves or generalized paroxysmal fast activity]"
      explanation: >-
        A 78-patient longitudinal cohort defines LGS by the co-occurrence of
        slow spike-wave bursts with multiple seizure types, the pairing this
        edge asserts.
  - target: Atypical Absence Seizures
    causal_link_type: DIRECT
    description: >-
      The diffuse slow (<2.5 Hz) spike-and-wave discharge is the electrographic
      correlate of the atypical absence seizures seen clinically.
  - target: Nonconvulsive Status Epilepticus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Prolonged, near-continuous slow spike-and-wave activity underlies the
      episodes of nonconvulsive (atypical absence) status epilepticus that
      recur over the disease course.
- name: Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
  description: >-
    The second defining electrographic feature is sleep-activated generalized
    paroxysmal fast activity (GPFA), the correlate of tonic seizures, which are
    the most characteristic seizure type of LGS and predominate in non-REM
    sleep. This node captures the single concept of fast-activity/tonic seizure
    generation.
  role: central_effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:25400619
    reference_title: Conceptualizing lennox-gastaut syndrome as a secondary network epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Scalp EEG of the tonic seizures of LGS is characterized by a diffuse high-voltage slow transient evolving into generalized low-voltage fast activity, likely reflecting sustained fast neuronal firing over a wide cortical area."
    explanation: >-
      Ties the tonic seizure directly to its fast-activity electrographic
      correlate and interprets it as sustained firing across a wide cortical
      area, which is the generation mechanism this node names.
  - reference: PMID:20149600
    reference_title: "Lennox-Gastaut syndrome in adulthood: clinical and EEG features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On the contrary, sleep EEG showed the persistence of DFR in all."
    explanation: >-
      Sleep-recorded diffuse fast rhythms persisted in all 27 adults even after
      waking slow spike-wave had resolved in most, supporting the non-REM
      sleep activation of the fast-activity discharge that this node asserts.
  - reference: PMID:24902608
    reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PFA-robust fMRI signal increases were observed in frontal and parietal association cortical areas, thalamus, and pons, with simultaneous increases in both \"attention\" and resting-state (default mode) networks, a highly unusual pattern."
    explanation: >-
      Maps the generalized paroxysmal fast activity of this node onto a specific
      cortical-thalamic-pontine network, distinguishing it from the slow
      spike-and-wave pattern recorded in the same patients.
  - reference: PMID:36114808
    reference_title: "Paroxysmal fast activity is a biomarker of treatment response in deep brain stimulation for Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Across all patient EEGs, the average number of GPFA discharges per hour of sleep was 138 (IQR =72-258)."
    explanation: >-
      Quantifies the generalized paroxysmal fast activity burden recorded per
      hour of sleep in adults with LGS. The quote establishes the magnitude of
      the discharge burden during sleep; it does not itself distinguish REM from
      non-REM, which the PMID:20149600 sleep-EEG item above speaks to.
  downstream:
  - target: Atonic Drop Attack Generation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Tonic and related discharges contribute to sudden tone changes producing
      drop attacks.
  - target: Multiple Drug-Resistant Seizure Types
    causal_link_type: DIRECT
    description: >-
      Generalized paroxysmal fast activity contributes the tonic component to the
      multiple co-occurring, treatment-resistant seizure types that define the
      syndrome. This edge carries no citation on purpose: the drug-resistance
      quote that was attached here attests a property of the target node, not
      this source-to-target step, and has been moved onto that node.
  - target: Tonic Seizures
    causal_link_type: DIRECT
    description: >-
      Sleep-activated generalized paroxysmal fast activity is the electrographic
      correlate of the tonic seizures that are the most characteristic seizure
      type of LGS.
- name: Atonic Drop Attack Generation
  description: >-
    Sudden loss (atonic) or brief increase (tonic) of postural tone produces
    drop attacks (astatic seizures), a major source of injury in LGS. This node
    captures the single concept of drop-attack generation, distinct from the
    tonic and absence seizure mechanisms above.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:37823366
    reference_title: "Added value of corpus callosotomy following vagus nerve stimulation in children with Lennox-Gastaut syndrome: A multicenter, multinational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The dominant seizure type was drop attacks (tonic or atonic) in 102 patients."
    explanation: >-
      In a multinational series of 127 children with LGS, drop attacks of either
      tonic or atonic type dominated the seizure burden, supporting both the
      prominence of this node and its dual tone-change mechanism.
  - reference: PMID:40937826
    reference_title: "Epileptic drop attacks: More than just atonic seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "drop attacks are rarely pure atonic seizures but are often epileptic spasms or other types of seizures with increased muscle tone"
    explanation: >-
      Video-EEG-electromyography evidence supports the increased-tone half of
      this node's mechanism but qualifies its atonic framing: pure atonic falls
      are the exception, and epileptic spasms account for many drop attacks, so
      the node's name should not be read as a claim that the mechanism is
      predominantly atonic.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."
    explanation: >-
      Establishes atonic seizures as a recurrent component of the LGS seizure
      repertoire (34.8% of 1167 pooled patients), substantiating drop-attack
      generation as a distinct mechanism node rather than an occasional feature.
  downstream:
  - target: Multiple Drug-Resistant Seizure Types
    causal_link_type: DIRECT
    description: >-
      Drop attacks are one of the multiple drug-resistant seizure types
      comprising the syndrome.
  - target: Atonic Seizures (Drop Attacks)
    causal_link_type: DIRECT
    description: >-
      Sudden loss of postural tone produces the atonic (astatic) drop attacks
      observed clinically, a major source of falls and injury.
- name: Interictal Epileptiform Activity-Driven Cognitive Impairment
  description: >-
    LGS is a developmental and epileptic encephalopathy: beyond any cognitive
    effect of the underlying cause, the frequent seizures and near-continuous
    interictal epileptiform activity are themselves thought to impair cognitive
    development and drive stagnation or regression. This node captures the single
    concept of the epileptic-encephalopathy contribution to cognition.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:26945476
    reference_title: "Abnormal cognitive network interactions in Lennox-Gastaut syndrome: A potential mechanism of epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal interactions were present during fMRI periods with and without discharges, indicating that impaired network behavior may endure during periods without scalp-detectable epileptic activity."
    explanation: >-
      Task-free EEG-fMRI in 15 patients versus 17 controls shows the cognitive
      networks recruited by LGS discharges are persistently disorganised between
      discharges, the mechanism by which epileptiform activity could impair
      cognition beyond the ictal event itself.
  - reference: PMID:28295228
    reference_title: Cognitive network reorganization following surgical control of seizures in Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This case illustrates that the epileptic process of LGS can directly contribute to abnormal network organization, and that this network disruption may be reversible."
    explanation: >-
      Pre/post-surgical fMRI in a child whose seizures remitted after resection
      provides the directional evidence this node needs -- removing the epileptic
      activity reorganised the cognitive networks -- though as a single case it
      does not quantify how much of the cognitive burden is activity-driven.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Longer duration of SSW discharges and disorganized background are associated with poor outcome."
    explanation: >-
      Links the burden of interictal epileptiform activity to worse outcome,
      consistent with the developmental-and-epileptic-encephalopathy claim that
      ongoing epileptiform activity itself contributes to the cognitive
      trajectory. Graded INDIRECT because the association is correlational and
      cannot separate an activity-driven effect from severity of the underlying
      etiology, which is the open question recorded in the attached
      knowledge-gap discussion.
  downstream:
  - target: Cognitive Impairment and Developmental Plateau
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Ongoing epileptiform activity contributes to the cognitive plateau and
      regression characteristic of the syndrome.
    evidence:
    - reference: PMID:26778176
      reference_title: "Epileptic encephalopathy: Use and misuse of a clinically and conceptually important concept."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "recent studies demonstrate that seizures and interictal epileptiform discharges can disrupt distributed neural networks that underpin cognitive functions, both temporarily and permanently"
      explanation: >-
        States the mechanism this edge asserts - interictal discharges, not only
        seizures, disrupting the networks that support cognition. Evidence
        source is OTHER because this is a conceptual review.
    - reference: PMID:30255934
      reference_title: "Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "supports the impression that the seizures themselves contribute to the cognitive decline and disability"
      explanation: >-
        Amelioration of intellectual disability after successful epilepsy
        surgery is the strongest available human argument that the epileptic
        activity contributes causally, rather than both being consequences of
        the underlying etiology.
  - target: Epileptic Encephalopathy
    causal_link_type: DIRECT
    description: >-
      Frequent seizures together with abundant interictal epileptiform activity
      constitute the epileptic encephalopathy itself, the clinical designation
      of this mechanism.
    evidence:
    - reference: PMID:26778176
      reference_title: "Epileptic encephalopathy: Use and misuse of a clinically and conceptually important concept."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The term epileptic encephalopathy (EE) denotes a process by which epileptic activity adversely affects brain function over and above the underlying etiology."
      explanation: >-
        Defines epileptic encephalopathy as exactly the process this node
        models - an effect of the epileptic activity itself, separable from the
        effect of the underlying cause. Evidence source is OTHER because this is
        a conceptual review.
- name: Multiple Drug-Resistant Seizure Types
  description: >-
    The clinical hallmark of LGS is the co-occurrence of several seizure types
    in one child, characteristically tonic, atonic, and atypical absence
    seizures, that are typically resistant to antiseizure medications. This node
    captures the single concept of the multiple-drug-resistant-seizure endpoint
    and conforms to the shared epilepsy final common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:30255934
    reference_title: "Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most LGS patients continued with refractory seizures"
    explanation: >-
      A prospective community-based cohort establishes that the seizures remain
      drug resistant over long follow-up, which is the defining property this
      node asserts. Moved here from the incoming causal edge, where the same
      quote attested this node's property rather than the source-to-target step.
  - reference: PMID:37212330
    reference_title: Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most individuals with LGS will require treatment with multiple ASMs."
    explanation: >-
      Review of randomized double-blind placebo-controlled trials in LGS
      concludes that polypharmacy is the norm, the practical expression of the
      drug resistance this endpoint node asserts.
  - reference: PMID:25616450
    reference_title: Long-term prognosis of patients with Lennox--Gastaut syndrome in recent decades.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For a mean follow-up duration of 19.3 years (range 8.3-32.5 years), finally sixteen patients (23.5%) were seizure-free."
    explanation: >-
      Quantifies the drug-resistant endpoint: even with ketogenic diet and
      epilepsy surgery available, fewer than a quarter of 68 patients reached
      seizure freedom over a mean of 19 years.
  - reference: PMID:29126048
    reference_title: "Lennox-Gastaut syndrome in adulthood: Long-term clinical follow-up of 38 patients and analysis of their recorded seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All of our patients had 3 or more seizure types during their clinical history."
    explanation: >-
      Confirms the multiplicity half of this node's claim: every one of 38
      adults with LGS had at least three distinct seizure types over the disease
      course.
  - reference: PMID:29124439
    reference_title: "Lennox-Gastaut syndrome: a comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The seizures in LGS are usually drug-resistant, and complete seizure control with resolution of intellectual and psychosocial dysfunction is often not achievable."
    explanation: >-
      States the drug resistance that defines this endpoint node and explains
      why LGS management targets reduction of the most injurious seizures rather
      than seizure freedom.
  - reference: PMID:34798494
    reference_title: "Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the last follow-up (call), 14 patients (17.9%) were seizure-free for at least 12 months."
    explanation: >-
      Quantifies the persistence of the drug-resistant seizure endpoint in a
      78-patient cohort followed a mean of 9.3 years into adulthood: fewer than
      one in five achieved a year of seizure freedom.
- name: Cognitive Impairment and Developmental Plateau
  description: >-
    Most children with LGS develop intellectual disability with developmental
    plateau or regression and frequent behavioural problems. This node captures
    the single concept of the cognitive/developmental outcome, the endpoint of
    both the underlying etiology and the epileptic encephalopathy.
  role: consequence
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:25616450
    reference_title: Long-term prognosis of patients with Lennox--Gastaut syndrome in recent decades.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In cognitive terms, 94.7% of patients exhibited moderate to profound mental retardation."
    explanation: >-
      In 68 adults followed a mean of 19.3 years, almost all had moderate to
      profound intellectual disability, quantifying the cognitive endpoint of
      this node.
  - reference: PMID:20149600
    reference_title: "Lennox-Gastaut syndrome in adulthood: clinical and EEG features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A moderate to severe cognitive impairment was observed in 26/27 patients."
    explanation: >-
      Independent adult LGS cohort reproduces the near-universal cognitive
      outcome, in patients aged 40-59 years and therefore decades after onset.
  - reference: PMID:34798494
    reference_title: "Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While intellectual dysfunction may not be evident at the onset of the disease, cognitive impairment usually becomes apparent over time, and almost all patients would suffer from poor social outcomes in their adulthood."
    explanation: >-
      Directly supports the plateau/regression framing of this node: cognition
      is often unremarkable at onset and deteriorates relative to expectation
      over the disease course, ending in near-universal poor adult social
      outcome.
  - reference: PMID:29124439
    reference_title: "Lennox-Gastaut syndrome: a comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This syndrome is often associated with long-term adverse effects on intellectual development, social functioning, and independent living."
    explanation: >-
      Review-level statement of the cognitive and functional endpoint modeled by
      this node.
  downstream:
  - target: Intellectual Disability
    causal_link_type: DIRECT
    description: >-
      The developmental plateau or regression is expressed clinically as
      intellectual disability in most affected children.
    evidence:
    - reference: PMID:34798494
      reference_title: "Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "While intellectual dysfunction may not be evident at the onset of the disease, cognitive impairment usually becomes apparent over time"
      explanation: >-
        A 78-patient cohort followed for a mean of 9.3 years shows the
        impairment emerging over the disease course rather than being present
        at onset, which is the plateau-to-disability progression this edge
        asserts.
  - target: Behavioral Abnormalities
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Hyperactivity, aggression, and autistic features accompany the cognitive
      outcome and add to the disability burden.
phenotypes:
- name: Tonic Seizures
  description: >-
    Tonic seizures, often nocturnal and sleep-activated, are the most
    characteristic seizure type of LGS.
  phenotype_term:
    preferred_term: Generalized tonic seizure
    term:
      id: HP:0010818
      label: Generalized tonic seizure
  evidence:
  - reference: PMID:21790560
    reference_title: "Definition and natural history of Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients have tonic seizures during sleep that may be subtle"
    explanation: >-
      Review of the definition and natural history of LGS states that tonic
      seizures, characteristically sleep-activated, occur in all patients.
  - reference: PMID:29126048
    reference_title: "Lennox-Gastaut syndrome in adulthood: Long-term clinical follow-up of 38 patients and analysis of their recorded seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent seizure types at follow-up were atypical absences (28/38), tonic (28/38), generalized tonic-clonic (17/38), focal (11/38), and myoclonic seizures (9/38)."
    explanation: >-
      Long-term follow-up of 38 adults with LGS found tonic seizures among the
      two most prevalent seizure types.
  - reference: PMID:39700524
    reference_title: "Refining management strategies for Lennox-Gastaut syndrome: Updated algorithms and practical approaches."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "characterized by multiple types of drug-resistant seizures (which must include tonic seizures)"
    explanation: >-
      Expert consensus guidance states that the drug-resistant seizure
      repertoire of LGS must include tonic seizures, establishing them as the
      obligate seizure type of the syndrome.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."
    explanation: >-
      Pooled systematic review of 1167 patients showing tonic seizures are the
      single most frequent seizure type in LGS (74.5%), supporting their status as
      the most characteristic seizure type of the syndrome.
- name: Atonic Seizures (Drop Attacks)
  description: >-
    Atonic (astatic) seizures cause sudden loss of postural tone and drop
    attacks with frequent falls and injuries.
  phenotype_term:
    preferred_term: Atonic seizure
    term:
      id: HP:0010819
      label: Atonic seizure
  evidence:
  - reference: PMID:29768152
    reference_title: "Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During the 28-day baseline period, the median number of drop seizures was 85 in all trial groups combined."
    explanation: >-
      In a 225-patient LGS trial cohort, drop seizures were frequent enough at
      baseline to serve as the primary endpoint, with a median of 85 per 28 days.
  - reference: PMID:29124439
    reference_title: "Lennox-Gastaut syndrome: a comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reduction in frequency of the most incapacitating seizures (e.g., drop attacks and tonic-clonic seizures) should be the major objective."
    explanation: >-
      Clinical review identifies drop attacks as one of the most incapacitating
      seizure types encountered in LGS.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."
    explanation: >-
      Establishes atonic seizures in 34.8% of pooled LGS patients, supporting drop
      attacks as a core rather than incidental component of the seizure
      repertoire.
- name: Atypical Absence Seizures
  description: >-
    Atypical absences with gradual onset/offset and incomplete loss of awareness
    accompany the slow spike-and-wave EEG pattern.
  phenotype_term:
    preferred_term: Atypical absence seizure
    term:
      id: HP:0007270
      label: Atypical absence seizure
  evidence:
  - reference: PMID:29126048
    reference_title: "Lennox-Gastaut syndrome in adulthood: Long-term clinical follow-up of 38 patients and analysis of their recorded seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent seizure types at follow-up were atypical absences (28/38), tonic (28/38), generalized tonic-clonic (17/38), focal (11/38), and myoclonic seizures (9/38)."
    explanation: >-
      Atypical absences were the most prevalent seizure type at follow-up in this
      adult LGS cohort, occurring in 28 of 38 patients.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."
    explanation: >-
      Establishes atypical absences as the second most frequent LGS seizure type
      (44.3% of pooled patients).
- name: Epileptic Encephalopathy
  description: >-
    Frequent seizures and abundant interictal epileptiform activity constitute
    an epileptic encephalopathy contributing to cognitive impairment.
  phenotype_term:
    preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
  evidence:
  - reference: PMID:29124439
    reference_title: "Lennox-Gastaut syndrome: a comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lennox-Gastaut syndrome (LGS) is considered an epileptic encephalopathy and is defined by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability."
    explanation: >-
      Review states that LGS is classified as an epileptic encephalopathy, with
      the defining triad including abundant interictal epileptiform activity.
- name: Intellectual Disability
  description: >-
    Most affected children have intellectual disability with developmental
    plateau or regression.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:25616450
    reference_title: "Long-term prognosis of patients with Lennox--Gastaut syndrome in recent decades."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In cognitive terms, 94.7% of patients exhibited moderate to profound mental retardation."
    explanation: >-
      In a cohort of 68 adults with LGS followed a mean of 19.3 years, nearly all
      had moderate to profound intellectual disability.
  - reference: PMID:29126048
    reference_title: "Lennox-Gastaut syndrome in adulthood: Long-term clinical follow-up of 38 patients and analysis of their recorded seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Besides epilepsy, intellectual disability and behavioral problems were prominent features."
    explanation: >-
      Adult LGS follow-up study reports intellectual disability as a prominent
      feature alongside the seizures.
  - reference: PMID:29124439
    reference_title: "Lennox-Gastaut syndrome: a comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is defined by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability"
    explanation: >-
      Intellectual disability is one of the three defining components of the
      LGS diagnostic triad.
  - reference: PMID:34798494
    reference_title: "Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While intellectual dysfunction may not be evident at the onset of the disease, cognitive impairment usually becomes apparent over time, and almost all patients would suffer from poor social outcomes in their adulthood."
    explanation: >-
      Supports the phenotype's "developmental plateau or regression" framing: in
      a 78-patient cohort followed into adulthood, cognitive impairment emerged
      over the disease course rather than being present from onset.
- name: Myoclonic Seizures
  description: >-
    Myoclonic seizures are a common additional seizure type in the LGS seizure
    repertoire.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
  evidence:
  - reference: PMID:29126048
    reference_title: "Lennox-Gastaut syndrome in adulthood: Long-term clinical follow-up of 38 patients and analysis of their recorded seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent seizure types at follow-up were atypical absences (28/38), tonic (28/38), generalized tonic-clonic (17/38), focal (11/38), and myoclonic seizures (9/38)."
    explanation: >-
      Myoclonic seizures were recorded in 9 of 38 adults with LGS, confirming
      them as an additional seizure type in the LGS repertoire.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."
    explanation: >-
      Establishes myoclonic seizures in 39.2% of pooled LGS patients, supporting
      their listing as a common additional seizure type.
- name: Generalized Tonic-Clonic Seizures
  description: >-
    Generalized (bilateral) tonic-clonic seizures occur commonly in addition to
    the defining seizure types.
  phenotype_term:
    preferred_term: Generalized tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: PMID:29126048
    reference_title: "Lennox-Gastaut syndrome in adulthood: Long-term clinical follow-up of 38 patients and analysis of their recorded seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent seizure types at follow-up were atypical absences (28/38), tonic (28/38), generalized tonic-clonic (17/38), focal (11/38), and myoclonic seizures (9/38)."
    explanation: >-
      Generalized tonic-clonic seizures were present in 17 of 38 adults with LGS
      at follow-up.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."
    explanation: >-
      Establishes generalized seizures in 38.5% of pooled LGS patients, supporting
      bilateral tonic-clonic seizures as a common addition to the defining seizure
      types.
- name: Nonconvulsive Status Epilepticus
  description: >-
    Episodes of nonconvulsive status epilepticus (often with tonic and atypical
    absence features) recur over the disease course and are strongly associated
    with severe intellectual disability.
  phenotype_term:
    preferred_term: Nonconvulsive status epilepticus
    term:
      id: HP:0031475
      label: Status epilepticus without prominent motor symptoms
  evidence:
  - reference: PMID:11071139
    reference_title: "Nonconvulsive status epilepticus--a possible cause of mental retardation in patients with Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four independent risk factors for severe mental retardation were identified by multivariate analysis. These were in a decreasing order of importance: nonconvulsive status epilepticus (NCSE), odds ratio (OR) 25.2"
    explanation: >-
      Multicentre study of 101 patients with LGS documents nonconvulsive status
      epilepticus in the cohort and identifies it as the strongest independent
      risk factor for severe intellectual disability.
  - reference: PMID:38976954
    reference_title: "A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tonic seizures (74.5 %) were most frequent followed by atypical absences (44.3 %), myoclonic (39.2 %), generalized (38.5 %), atonic (34.8 %), epileptic spasm (15.9 %), focal (11.4 %) and non-convulsive status epilepticus (7.0 %)."
    explanation: >-
      Reports non-convulsive status epilepticus in 7.0% of pooled LGS patients.
      This is a cross-sectional figure pooled across EEG studies, so it bounds
      how often NCSE is captured at a single assessment rather than how often it
      recurs over the disease course, which is what this phenotype's description
      claims and what the long-term series cited above speaks to.
- name: Global Developmental Delay
  description: >-
    Global developmental delay frequently precedes or accompanies seizure onset
    and evolves into intellectual disability.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:21790560
    reference_title: "Definition and natural history of Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cognitive stagnation and behavioral problems are seen in almost all patients and lead to a life of dependency."
    explanation: >-
      Review reports developmental stagnation in almost all patients with LGS,
      the developmental-delay counterpart of the seizure phenotype.
  - reference: PMID:11071139
    reference_title: "Nonconvulsive status epilepticus--a possible cause of mental retardation in patients with Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At the last follow-up, 38% of the patients could not speak, 21% were unable to walk and only 4% were free of seizures."
    explanation: >-
      Long-term follow-up of 101 patients quantifies the global developmental
      impairment across speech and motor domains.
  - reference: PMID:33764203
    reference_title: "Evolution of Infantile Spasms to Lennox-Gastaut Syndrome: What Is There to Know?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Developmental delay and history of seizures prior to the onset of infantile spasms were identified as risk factors for the development of Lennox-Gastaut syndrome (P = .003) as was poor response to first treatment for spasms (P = .004)."
    explanation: >-
      Directly supports the "precedes seizure onset" claim in this phenotype's
      description: in a 97-child infantile-spasms cohort, developmental delay was
      a risk factor measured before the LGS diagnosis was made, not merely a
      later consequence of it.
- name: Behavioral Abnormalities
  description: >-
    Behavioral problems are common and add to the disability burden. The
    features the cited literature attributes to LGS specifically are autistic
    features and generally sluggish behavior; the remaining sources report
    behavioral problems as prominent without characterizing them further.
  phenotype_term:
    preferred_term: Behavioral abnormality
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:29126048
    reference_title: "Lennox-Gastaut syndrome in adulthood: Long-term clinical follow-up of 38 patients and analysis of their recorded seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Besides epilepsy, intellectual disability and behavioral problems were prominent features."
    explanation: >-
      Adult LGS follow-up study reports behavioral problems as a prominent
      feature of the phenotype.
  - reference: PMID:21790560
    reference_title: "Definition and natural history of Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cognitive stagnation and behavioral problems are seen in almost all patients and lead to a life of dependency."
    explanation: >-
      Review reports behavioral problems in almost all patients with LGS and
      links them to the disability burden.
  - reference: PMID:39854828
    reference_title: "Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by multiple drug-resistant seizure types, specific electroencephalogram (EEG) patterns, and significant cognitive and behavioral impairments"
    explanation: >-
      Review characterizes LGS as involving significant behavioral impairment
      alongside the seizure and EEG features.
  - reference: PMID:14725841
    reference_title: "Behavioral aspects of pediatric epilepsy syndromes."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The behavioral problems reported with Lennox-Gastaut syndrome also include autistic features, as well as generally sluggish behavior."
    explanation: >-
      Sources the two behavioural features this phenotype's description now
      names for LGS specifically. The same review attributes hyperactivity to
      Dravet syndrome and aggression to Landau-Kleffner syndrome, not to LGS,
      which is why the description no longer claims them; it also cautions that
      syndrome-behaviour reports of this kind are largely anecdotal and lack
      validated behavioural measures.
genetic:
- name: Genetically heterogeneous developmental and epileptic encephalopathy genes
  notes: >-
    LGS has no single causative gene. A minority of cases carry pathogenic
    variants in developmental and epileptic encephalopathy genes (reported
    examples include SCN1A, SCN2A, SCN8A, STXBP1, CHD2, DNM1, GABRB3, FOXG1,
    ALG13, and others); many cases are structural or of unknown cause. Most
    cases are sporadic, and when monogenic the causative variants are typically
    de novo. Contributing genes are named here rather than asserting a single
    Mendelian locus.
  evidence:
  - reference: PMID:23934111
    reference_title: "De novo mutations in epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "de novo mutations in patients with two classical epileptic encephalopathies: infantile spasms (n = 149) and Lennox-Gastaut syndrome (n = 115)."
    explanation: >-
      The Epi4K trio-exome study established that a substantial fraction of LGS
      is caused by de novo variants, sequencing 115 LGS probands alongside
      infantile spasms cases.
  - reference: PMID:23934111
    reference_title: "De novo mutations in epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."
    explanation: >-
      Identifies GABRB3 and ALG13 as genome-wide-significant developmental and
      epileptic encephalopathy genes in the IS/LGS cohort, illustrating the
      genetic heterogeneity of LGS.
treatments:
- name: Broad-Spectrum Antiseizure Medication
  description: >-
    First-line pharmacotherapy uses broad-spectrum antiseizure medications
    (e.g., valproate, lamotrigine); LGS seizures are typically drug-resistant and
    require combination therapy. Narrow-spectrum sodium-channel blockers
    (carbamazepine, oxcarbazepine, phenytoin) and vigabatrin can aggravate
    atypical absence and myoclonic seizures and are generally avoided.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:37212330
    reference_title: Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Valproate continues to be considered the first-line treatment, despite the absence of RDBCTs specifically in LGS."
    explanation: >-
      Review of the LGS trial evidence places valproate first-line while making
      the strength of that recommendation explicit -- it rests on clinical
      practice rather than on a randomized double-blind trial in LGS.
  - reference: PMID:20158289
    reference_title: Medical management of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Valproate, lamotrigine and topiramate were considered recently by expert panels in the US and Europe to be the first-line drugs."
    explanation: >-
      Independent expert-panel consensus on both continents names the same
      broad-spectrum agents as first-line, supporting the composition of this
      treatment.
  - reference: PMID:9593229
    reference_title: Antiepileptic drug-induced worsening of seizures in children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An inappropriate choice of the AED (i.e., a purely pharmacodynamic mechanism) can induce worsening when CBZ or VGB is used in absence and myoclonic seizures."
    explanation: >-
      Supports the avoidance clause in this treatment's description:
      carbamazepine and vigabatrin aggravate exactly the atypical absence and
      myoclonic seizure types that form part of the LGS repertoire.
  - reference: PMID:39700524
    reference_title: "Refining management strategies for Lennox-Gastaut syndrome: Updated algorithms and practical approaches."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the recommended first-line treatment continues to be valproate. If this is ineffective as monotherapy, adjunctive therapy with, firstly, lamotrigine and secondly, rufinamide, is recommended."
    explanation: >-
      Expert consensus treatment algorithm places the broad-spectrum agents
      valproate and lamotrigine first in the LGS pharmacotherapy sequence.
  - reference: PMID:39854828
    reference_title: "Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proposed treatment algorithm emphasizes a personalized approach to LGS management, recommending valproate or clobazam as first-line treatments, followed by individualized combinations based on the specific patient profile and associated comorbidities."
    explanation: >-
      US expert-panel consensus algorithm naming valproate or clobazam as
      first-line therapy and combination treatment thereafter, supporting the
      broad-spectrum-first strategy described here.
- name: LGS-Indicated Adjunctive Antiseizure Agents
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Eight agents carry a specific FDA indication for LGS-associated seizures:
    clonazepam, felbamate, lamotrigine, topiramate, rufinamide, clobazam,
    cannabidiol, and fenfluramine. Note that the regulatory set and the set with
    randomized double-blind trial support are not the same list - clonazepam is
    FDA-approved without such a trial, and lamotrigine appears in both the
    first-line broad-spectrum entry and here.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cannabidiol
      term:
        id: CHEBI:69478
        label: cannabidiol
    - preferred_term: fenfluramine
      term:
        id: CHEBI:5000
        label: fenfluramine
    - preferred_term: rufinamide
      term:
        id: CHEBI:134966
        label: rufinamide
    - preferred_term: clobazam
      term:
        id: CHEBI:31413
        label: clobazam
  evidence:
  - reference: PMID:29768152
    reference_title: "Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "median percent reduction from baseline in drop-seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group"
    explanation: >-
      Randomized placebo-controlled trial (GWPCARE3) demonstrating that add-on
      cannabidiol reduces drop-seizure frequency in LGS, supporting its role as
      an LGS-indicated adjunctive agent.
  - reference: PMID:37212330
    reference_title: Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evidence from RDBCTs supports the use of cannabidiol, clobazam, felbamate, fenfluramine, lamotrigine, rufinamide, and topiramate as adjunct treatments for drop seizures."
    explanation: >-
      Names the adjunctive agents with randomized double-blind placebo-controlled
      trial support in LGS, which is the set this treatment entry lists.
  - reference: PMID:35499850
    reference_title: "Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The trial met its primary efficacy end point: patients in the 0.7-mg/kg/d fenfluramine group achieved a -19.9 percentage points (95% CI, -31.0 to -8.7 percentage points; P = .001) estimated median difference in drop seizures from baseline vs placebo."
    explanation: >-
      Phase 3 randomized placebo-controlled trial in 263 patients establishing
      adjunctive fenfluramine as effective against drop seizures in LGS.
  - reference: PMID:37212330
    reference_title: Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Percentage decreases in drop seizure frequency ranged from 68.3% with high-dose clobazam to 14.8% with topiramate."
    explanation: >-
      Qualifies the entry: the LGS-indicated adjuncts differ several-fold in
      effect size, so listing them together should not be read as claiming
      equivalent efficacy.
  - reference: PMID:39854828
    reference_title: "Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "eight anti-seizure medications (ASMs) have been specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of LGS: clonazepam, felbamate, lamotrigine, topiramate, rufinamide, clobazam, cannabidiol, and fenfluramine"
    explanation: >-
      Enumerates the antiseizure medications carrying a specific regulatory
      indication for LGS, supporting this treatment as a distinct
      LGS-indicated adjunctive class.
- name: Ketogenic Diet Therapy
  description: >-
    Ketogenic and modified Atkins diets are used for drug-resistant LGS seizures.
  treatment_term:
    preferred_term: ketogenic diet intake
    term:
      id: NCIT:C173168
      label: Ketogenic Diet
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:22443637
    reference_title: "Efficacy of the ketogenic diet in Lennox-Gastaut syndrome: a retrospective review of one institution's experience and summary of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "after 6 months, 36 (51%) achieved more than 50% seizure reduction, 16 (23%) experienced more than 90% seizure reduction, and 1 (1%) achieved seizure freedom."
    explanation: >-
      Largest single-institution LGS ketogenic-diet series (71 children) with an
      intent-to-treat analysis: about half responded, quantifying the benefit
      claimed for this treatment.
  - reference: PMID:22443637
    reference_title: "Efficacy of the ketogenic diet in Lennox-Gastaut syndrome: a retrospective review of one institution's experience and summary of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the literature, 88 of 189 (47%) children with LGS had more than 50% seizure reduction after 3 to 36 months of ketogenic diet treatment."
    explanation: >-
      Pooled literature figure reproduces the same response rate outside the
      reporting institution, so the estimate is not single-centre.
  - reference: PMID:25616450
    reference_title: Long-term prognosis of patients with Lennox--Gastaut syndrome in recent decades.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The KD was administered to 19 patients, five patients maintained a seizure free state during the KD but only one patient was able to maintain a seizure free state by continuing on a modified Atkins diet."
    explanation: >-
      Supports short-term efficacy while qualifying durability: seizure freedom
      achieved on the ketogenic diet was largely not maintained on a modified
      Atkins diet in long-term follow-up.
  - reference: PMID:39700524
    reference_title: "Refining management strategies for Lennox-Gastaut syndrome: Updated algorithms and practical approaches."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Nonpharmacological treatment approaches should be used in conjunction with ASM therapy and include ketogenic diet therapies, vagus nerve stimulation, and corpus callosotomy."
    explanation: >-
      Expert consensus guidance recommends ketogenic diet therapy as an
      adjunct to antiseizure medication in LGS.
  - reference: PMID:33871716
    reference_title: "Efficacy and safety of corpus callosotomy and ketogenic diet in children with Lennox Gastaut syndrome: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We selected 23 and 7 articles describing the efficacy of CC and KD in 436 and 185 LGS patients out of 217 search items, but none of the studies compared directly these two entities."
    explanation: >-
      Establishes the size of the pooled ketogenic-diet evidence base in LGS --
      seven studies in 185 patients -- and records that none of the included
      studies compared the diet with callosotomy directly. It sizes and
      qualifies the evidence base rather than demonstrating efficacy; the
      efficacy claims rest on the items above.
  - reference: PMID:33871716
    reference_title: "Efficacy and safety of corpus callosotomy and ketogenic diet in children with Lennox Gastaut syndrome: a systematic review and meta-analysis."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "CC is more efficacious than KD in reducing seizure frequency in patients with LGS, although it has relatively more adverse effects during the immediate perioperative period."
    explanation: >-
      Places dietary therapy below corpus callosotomy on seizure-frequency
      reduction. Graded INDIRECT because the conclusion rests on an indirect
      comparison: the review states that none of the pooled studies compared the
      two modalities head to head.
- name: Corpus Callosotomy
  description: >-
    Palliative corpus callosotomy is used to reduce drop attacks (tonic/atonic
    seizures) refractory to medication.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  therapeutic_modality: SURGERY
  evidence:
  - reference: PMID:37823366
    reference_title: "Added value of corpus callosotomy following vagus nerve stimulation in children with Lennox-Gastaut syndrome: A multicenter, multinational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, there was at least a 50% reduction in drop attacks and other seizures in 83% and 60%, respectively."
    explanation: >-
      In 127 children with LGS whose vagus nerve stimulation had failed,
      callosotomy halved drop attacks in 83%, supporting the palliative
      drop-attack indication this treatment states.
  - reference: PMID:37823366
    reference_title: "Added value of corpus callosotomy following vagus nerve stimulation in children with Lennox-Gastaut syndrome: A multicenter, multinational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Permanent morbidity occurred in 1.5%, with no mortality."
    explanation: >-
      Quantifies the surgical risk that makes this a viable palliative option in
      the same multinational series.
  - reference: PMID:40937826
    reference_title: "Epileptic drop attacks: More than just atonic seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recent studies suggest that epileptic spasms are cortically or hemispherically generated seizures and that disconnecting the corpus callosum potentially interrupts bilaterally synchronous seizure activities, supporting the rationale for surgery in patients with epileptic drop attacks."
    explanation: >-
      States the mechanistic rationale linking callosal disconnection to the
      bilaterally synchronous discharge that produces drop attacks.
  - reference: PMID:39700524
    reference_title: "Refining management strategies for Lennox-Gastaut syndrome: Updated algorithms and practical approaches."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Nonpharmacological treatment approaches should be used in conjunction with ASM therapy and include ketogenic diet therapies, vagus nerve stimulation, and corpus callosotomy."
    explanation: >-
      Expert consensus guidance lists corpus callosotomy among the
      nonpharmacological options for LGS.
  - reference: PMID:35989160
    reference_title: "Callosotomy vs Vagus Nerve Stimulation in the Treatment of Lennox-Gastaut Syndrome: A Systematic Review With Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For scenario 1 (seizure reduction \u2265 50%), CC had an incidence of 65% (95% CI, 37%-94%), with an I2 value of 82.7%; VNS had an incidence of 34% (95% CI, 11%-57%), with an I2 value of 80.7%."
    explanation: >-
      Meta-analysis of 14 callosotomy studies (107 patients) reporting that 65%
      achieved at least 50% seizure reduction, supporting palliative callosotomy
      in drug-resistant LGS. Note the wide confidence interval and high
      heterogeneity.
- name: Vagus Nerve Stimulation
  description: >-
    Vagus nerve stimulation is a palliative neuromodulation option for
    drug-resistant LGS.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  therapeutic_modality: DEVICE
  evidence:
  - reference: PMID:33188523
    reference_title: "Vagus nerve stimulation in patients with Lennox-Gastaut syndrome: A meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A random-effects model produced a pooled proportion of 54% (95% confidence intervals [CI]: 45%, 64%) of patients with LGS who responded to adjunctive VNS Therapy"
    explanation: >-
      Meta-analysis of 17 studies and 480 patients gives the pooled responder
      rate for adjunctive vagus nerve stimulation in LGS.
  - reference: PMID:33188523
    reference_title: "Vagus nerve stimulation in patients with Lennox-Gastaut syndrome: A meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Per an exploratory analysis, the calculated incidence of serious adverse events associated with VNS Therapy was 9% (95% CI: 5%, 14%)"
    explanation: >-
      Records the adverse-event burden alongside the response rate; the authors
      attribute the higher-than-expected rate to inconsistent definitions across
      the pooled studies rather than to a distinct hazard in LGS.
  - reference: PMID:37823366
    reference_title: "Added value of corpus callosotomy following vagus nerve stimulation in children with Lennox-Gastaut syndrome: A multicenter, multinational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although CC is more effective than VNS as the primary neurosurgical treatment for LGS-associated drop attacks, there are limited data regarding the added value of CC following VNS."
    explanation: >-
      Positions vagus nerve stimulation against corpus callosotomy for the
      drop-attack indication: it is the less effective of the two palliative
      options, which qualifies rather than contradicts its use here.
  - reference: PMID:39700524
    reference_title: "Refining management strategies for Lennox-Gastaut syndrome: Updated algorithms and practical approaches."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Nonpharmacological treatment approaches should be used in conjunction with ASM therapy and include ketogenic diet therapies, vagus nerve stimulation, and corpus callosotomy."
    explanation: >-
      Expert consensus guidance lists vagus nerve stimulation among the
      nonpharmacological options for LGS.
  - reference: PMID:35989160
    reference_title: "Callosotomy vs Vagus Nerve Stimulation in the Treatment of Lennox-Gastaut Syndrome: A Systematic Review With Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our analysis of LGS showed that the CC and VNS treatments are significantly beneficial to reducing seizures, without superiority between them."
    explanation: >-
      Head-to-head meta-analytic comparison finding both palliative options
      beneficial with overlapping confidence intervals, so neither is
      established as superior.
datasets: []
clinical_trials:
- name: NCT02224560
  phase: PHASE_III
  status: COMPLETED
  description: >-
    GWPCARE3: randomized, double-blind, placebo-controlled phase 3 trial of
    adjunctive cannabidiol (10 and 20 mg/kg/day) for drop seizures in children
    and adults with Lennox-Gastaut syndrome, reported in PMID:29768152.
  target_phenotypes:
  - preferred_term: Atonic seizure
    term:
      id: HP:0010819
      label: Atonic seizure
  - preferred_term: Generalized tonic seizure
    term:
      id: HP:0010818
      label: Generalized tonic seizure
  evidence:
  - reference: clinicaltrials:NCT02224560
    reference_title: "A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS)."
    explanation: >-
      ClinicalTrials.gov registration record establishing the trial's identity,
      LGS population, and drop-seizure primary endpoint.
  - reference: PMID:29768152
    reference_title: "Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "median percent reduction from baseline in drop-seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group"
    explanation: >-
      Reports the trial's primary-endpoint result for the higher cannabidiol
      dose.
- name: NCT03355209
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Two-part phase 3 study of fenfluramine (ZX008) as adjunctive therapy for
    seizures in children and adults with Lennox-Gastaut syndrome: a randomized,
    double-blind, placebo-controlled trial of two fixed doses followed by an
    open-label extension. Reported in PMID:35499850.
  target_phenotypes:
  - preferred_term: Atonic seizure
    term:
      id: HP:0010819
      label: Atonic seizure
  - preferred_term: Generalized tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: clinicaltrials:NCT03355209
    reference_title: "A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults With LGS"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS)."
    explanation: >-
      ClinicalTrials.gov registration record establishing the trial's design and
      LGS population.
  - reference: PMID:35499850
    reference_title: "Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More patients in the 0.7-mg/kg/d fenfluramine group achieved a 50% or greater response (22 of 87 [25%]; P = .02) vs placebo (9 of 87 [10%])."
    explanation: >-
      Reports the responder-rate result of the randomized phase of this trial.
differential_diagnoses:
- name: Atypical benign partial epilepsy (pseudo-Lennox syndrome)
  description: >-
    Pseudo-Lennox syndrome produces generalized minor seizures (atonic-astatic,
    myoclonic, atypical absence) with sleep-activated focal sharp waves, and is
    the classic misdiagnosis for LGS in a child with drop attacks.
  distinguishing_features:
  - >-
    Tonic seizures and bursts of generalized fast rhythms -- the two features
    most specific to LGS -- are absent in pseudo-Lennox syndrome.
  - >-
    The interictal EEG shows Rolandic-type focal sharp and slow waves that
    generalize in sleep, rather than the diffuse slow spike-and-wave of LGS.
  - >-
    The prognosis diverges: clinical remission is the rule in pseudo-Lennox
    syndrome, whereas LGS epilepsy is typically lifelong.
  evidence:
  - reference: PMID:11315196
    reference_title: 'Atypical "benign" partial epilepsy or pseudo-Lennox syndrome. Part I: symptomatology and long-term prognosis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No tonic seizures and no fast spike series (bursts of 10-20 Hz rhythms) were observed."
    explanation: >-
      In 43 children with atypical benign partial epilepsy, the two most
      LGS-specific features were absent, which is the discriminating
      observation.
  - reference: PMID:11315196
    reference_title: 'Atypical "benign" partial epilepsy or pseudo-Lennox syndrome. Part I: symptomatology and long-term prognosis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At last follow-up, 84% of patients were in clinical remission. All subjects older than age 15 were seizure-free."
    explanation: >-
      The prognostic divergence from LGS, in which seizures are typically
      lifelong and seizure freedom is reached by a minority.
  - reference: PMID:21790560
    reference_title: Definition and natural history of Lennox-Gastaut syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The differential diagnosis includes other symptomatic generalized epilepsies and pseudo-Lennox syndrome. Misdiagnosis is common."
    explanation: >-
      Names pseudo-Lennox syndrome as the differential and records that
      misdiagnosis is frequent, which is why this entry is listed.
discussions:
- discussion_id: gap_lgs_convergent_syndrome_vs_disease
  prompt: >-
    Is Lennox-Gastaut syndrome a single disease with a unifying network
    mechanism, or a convergent electroclinical endpoint that many distinct
    etiologies reach when they perturb the immature brain — and what network
    property, if any, actually defines membership?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Heterogeneous Etiologic Brain Insult
  - pathophysiology#Diffuse Thalamocortical Network Dysfunction
  rationale: >-
    LGS is defined by a characteristic triad that appears despite highly
    diverse structural, genetic, and metabolic causes, which is why this entry
    models a heterogeneous insult converging on a shared network node rather
    than a single lesion. Whether there is a genuine unifying mechanism (a
    specific thalamocortical network signature that all cases share) or whether
    LGS is essentially a stereotyped way the immature network fails, with no
    deeper common cause, remains debated. The answer determines whether LGS
    should be modeled as one disease entity or as a syndromic label over many
    diseases, and whether a network-level therapeutic target could exist.
  evidence:
  - reference: PMID:24902608
    reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."
    explanation: >-
      Supports a shared-network view by showing common cerebral networks engaged
      by the defining discharges across patients, the empirical basis for the
      convergent-syndrome position.
  proposed_experiments:
  - experiment_id: exp_lgs_shared_network_signature
    name: Cross-etiology network-signature comparison in LGS
    description: >-
      Using simultaneous EEG and functional MRI across patients with LGS of
      distinct etiologies (structural, genetic, post-infantile-spasms), test
      whether slow spike-and-wave and paroxysmal fast activity recruit the same
      thalamocortical hubs regardless of cause, and whether a shared network
      signature separates LGS from other generalized epilepsies.
    experiment_type:
      preferred_term: EEG-functional MRI network comparison experiment
    readouts:
    - name: Shared network recruitment
      target: pathophysiology#Diffuse Thalamocortical Network Dysfunction
      assays:
      - preferred_term: functional magnetic resonance imaging assay
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Non-LGS generalized epilepsy comparators
      description: Patients with other generalized epilepsies imaged under the same protocol.
    decision_criterion: >-
      A unifying-mechanism interpretation is supported if a common
      thalamocortical network is recruited across etiologies and distinguishes
      LGS from comparators; a purely convergent-label interpretation is favored
      if the network signature tracks etiology rather than the LGS diagnosis.
    would_support:
    - pathophysiology#Diffuse Thalamocortical Network Dysfunction

- discussion_id: gap_lgs_tonic_seizure_gpfa_circuit_mechanism
  prompt: >-
    What circuit generates the tonic seizures and their electrographic
    correlate, sleep-activated generalized paroxysmal fast activity — the
    near-specific hallmark of LGS — and why is it activated by non-REM sleep?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
  rationale: >-
    Generalized paroxysmal fast activity and tonic seizures are the most
    LGS-specific features, yet the circuit that produces them is poorly
    resolved. Competing accounts implicate thalamocortical mechanisms, brainstem
    arousal systems, and a sleep-state gating that selectively activates the
    discharge in non-REM sleep. Resolving the generator matters directly for
    neuromodulation targeting (for example centromedian thalamic stimulation)
    and for understanding why the hallmark seizure type is sleep-activated.
  evidence:
  - reference: PMID:24902608
    reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."
    explanation: >-
      Identifies the network engaged by paroxysmal fast activity but does not
      resolve the specific generator or the sleep-state gating, which is the
      open question.
  proposed_experiments:
  - experiment_id: exp_lgs_gpfa_generator_localization
    name: Sleep-state localization of the paroxysmal fast activity generator
    description: >-
      Combine intracranial or high-density scalp recordings with sleep staging
      and thalamic recording where available to localize the onset of
      paroxysmal fast activity and test whether non-REM sleep gates a
      thalamocortical or brainstem generator.
    experiment_type:
      preferred_term: intracranial seizure-onset localization experiment
    readouts:
    - name: Fast-activity onset localization by sleep state
      target: pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
      assays:
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Wake-state recordings
      description: Matched recordings during wakefulness to isolate the sleep-gating effect.
    decision_criterion: >-
      A generator is supported if paroxysmal fast activity reproducibly arises
      from a defined thalamocortical or brainstem node under non-REM sleep and
      not during matched wakefulness.
    would_support:
    - pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

- discussion_id: gap_lgs_epileptic_encephalopathy_cognition_reversibility
  prompt: >-
    How much of the cognitive impairment in LGS is driven by ongoing seizures
    and interictal epileptiform activity (and therefore potentially modifiable
    by seizure control) versus fixed injury from the underlying etiology?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Interictal Epileptiform Activity-Driven Cognitive Impairment
  - pathophysiology#Cognitive Impairment and Developmental Plateau
  rationale: >-
    The developmental and epileptic encephalopathy concept holds that the
    epileptic activity itself contributes to cognitive decline beyond the
    underlying cause. If a substantial fraction of the cognitive burden is
    activity-driven, then earlier and more complete seizure control could
    improve developmental outcome; if it is fixed etiologic injury, cognitive
    prognosis would be largely independent of seizure control. Because LGS is
    typically drug-resistant, this fraction has been very hard to estimate, and
    it is a central open question with direct therapeutic stakes.
  proposed_experiments:
  - experiment_id: exp_lgs_seizure_control_cognition_coupling
    name: Coupling of seizure/EEG burden to cognitive trajectory in LGS
    description: >-
      In a prospective LGS cohort, relate quantitative interictal
      epileptiform burden and seizure frequency to longitudinal
      neurodevelopmental trajectory, and where an intervention achieves marked
      seizure reduction, test whether cognitive trajectory inflects
      independently of etiology.
    experiment_type:
      preferred_term: longitudinal cohort coupling experiment
    readouts:
    - name: Cognitive trajectory versus epileptiform burden
      target: pathophysiology#Cognitive Impairment and Developmental Plateau
      assays:
      - preferred_term: neuropsychological assessment
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Etiology-stratified comparison
      description: Stratify by etiology to separate activity-driven from fixed injury effects.
    decision_criterion: >-
      An activity-driven contribution is supported if reductions in epileptiform
      burden are followed by improvement or stabilization of cognitive
      trajectory within etiology strata; a fixed-injury interpretation is
      favored if trajectory tracks etiology regardless of seizure control.
    would_support:
    - pathophysiology#Interictal Epileptiform Activity-Driven Cognitive Impairment

- discussion_id: gap_lgs_animal_model_convergent_syndrome_fidelity
  prompt: >-
    Can any animal model reproduce the convergent LGS electroclinical syndrome
    (tonic seizures with generalized paroxysmal fast activity plus slow
    spike-and-wave), or do current single-gene models only capture one
    etiologic entry point into the syndrome?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Diffuse Thalamocortical Network Dysfunction
  - pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
  rationale: >-
    Because LGS is a convergent syndrome rather than a single-gene disease, a
    faithful model would need to reproduce the shared network phenotype, not
    just one causative lesion. Existing models (for example GABRB3 knock-in
    mice) recapitulate a single genetic etiology and some seizure features, but
    whether they reproduce the defining tonic-seizure and paroxysmal
    fast-activity network signature of human LGS is uncertain. This is a
    translational-validity gap, distinct from an absence of evidence: model
    data exist, but their fidelity to the convergent human syndrome is the open
    question.
  evidence:
  - reference: PMID:23934111
    reference_title: "De novo mutations in epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."
    explanation: >-
      Identifies GABRB3 as an LGS-associated gene whose mouse models test a
      single etiology; the mismatch question is whether such single-gene models
      reproduce the convergent LGS network phenotype.
  proposed_experiments:
  - experiment_id: exp_lgs_model_network_phenotype_fidelity
    name: Network-phenotype fidelity testing across LGS etiologic models
    description: >-
      Phenotype several distinct LGS etiologic models (a GABA-A receptor model,
      an mTOR/structural model, and a synaptic model) with the same
      sleep-EEG and network readouts used clinically, testing whether any
      reproduces tonic seizures with sleep-activated fast activity and slow
      spike-and-wave.
    experiment_type:
      preferred_term: cross-model network phenotyping experiment
    readouts:
    - name: Tonic seizure and fast-activity phenotype
      target: pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
      assays:
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Wild-type littermates
      description: Matched wild-type animals recorded under identical protocols.
    decision_criterion: >-
      Human fidelity for a model is supported if it reproduces the sleep-activated
      paroxysmal fast activity and tonic seizure signature; models that show only
      isolated seizures without the network signature are flagged as capturing an
      etiologic entry point rather than the LGS syndrome.
    would_support:
    - pathophysiology#Diffuse Thalamocortical Network Dysfunction

📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Lennox-Gastaut Syndrome · 2026-07-17T19:23:56Z · View source

De-novo curation of Lennox-Gastaut syndrome (MONDO:0016532) as a granular, unbundled developmental and epileptic encephalopathy entry: 10 single-concept pathophysiology nodes (heterogeneous insult -> age-dependent evolution from infantile spasms -> diffuse thalamocortical network dysfunction -> cortical excitation-inhibition imbalance -> slow spike-and-wave generation / generalized paroxysmal fast activity + tonic seizures -> atonic drop attacks -> multiple drug-resistant seizure types; parallel interictal-epileptiform-activity -> cognitive-impairment arm), with two conforms_to links to the epilepsy_excitation_inhibition_imbalance module. Deep research provider: claude_code (research/Lennox-Gastaut_Syndrome-deep-research-claude_code.md; 10 web searches, 13 citations). Evidence uses snippet-verified PMIDs: 24902608 (secondary network epilepsies), 23934111 (Epi4K de novo, GABRB3/ALG13), 29768152 (cannabidiol GWPCARE3 RCT). Added a discussions section with 4 items: convergent-syndrome-vs-disease controversy, tonic-seizure/GPFA circuit knowledge gap, epileptic-encephalopathy cognition-reversibility knowledge gap, and an animal-model human-fidelity mismatch. No GeneReviews article exists (heterogeneous syndrome). All snippets manually confirmed as exact substrings; schema/term/reference validation and folded-hyphen check pass.

Claude Code ▸

1. Disease Information

claude-haiku-4-5-20251001, claude-opus-4-8 13 citations 2026-07-17T15:15:03.681936

1. Disease Information

Overview. Lennox-Gastaut Syndrome is a severe, childhood-onset developmental and epileptic encephalopathy (DEE) defined by a triad: 1. Multiple seizure types — obligatorily including tonic seizures (the hallmark, often nocturnal) plus atypical absences, atonic/drop attacks, and frequently myoclonic, generalized tonic-clonic, and nonconvulsive status epilepticus; 2. A characteristic EEG signature — diffuse slow spike-and-wave complexes (<2.5–3 Hz) in the awake state and bursts of generalized paroxysmal fast activity (GPFA, ~10–20 Hz) during sleep (GPFA is considered the electrographic correlate of tonic seizures and is near-specific for LGS); 3. Cognitive and behavioral impairment — intellectual disability that is usually progressive.

Seizures are characteristically drug-resistant, and the encephalopathy is lifelong. The 2022 ILAE syndrome classification for the first time laid down formal diagnostic criteria, which matters because the older literature is muddied by inconsistent inclusion definitions.

Key identifiers (⚠️ verify against OAK/OLS before curation — several are heterogeneous): - MONDO: MONDO:0016532 (Lennox-Gastaut syndrome) — verify in local sqlite:obo:mondo per the new-MONDO-term cache-miss memory note. - OMIM: 606369 is cross-referenced by GARD/Orphanet, but note that the live OMIM entry 606369 currently carries the title "Macrocephaly and Epileptic Encephalopathy" — OMIM does not maintain a single clean LGS phenotype entry because the syndrome is genetically heterogeneous. Individual genetic causes have their own DEE MIM numbers. Treat the OMIM mapping as soft. - Orphanet: ORPHA:2382 (confirmed). - ICD-10: G40.812 / G40.813 (intractable, with/without status epilepticus). ICD-11: 8A62.1 (approximate — verify). - MeSH: D065768 (Lennox Gastaut Syndrome). UMLS: C0520725.

Synonyms / alternative names: Lennox syndrome; Lennox-Gastaut-Dravet (obsolete lumping); "epileptic encephalopathy with slow spike-wave"; historically overlapped with "petit mal variant" and "childhood epileptic encephalopathy." It is distinct from — but often evolves out of — West syndrome / infantile spasms.

Data provenance. Information here is overwhelmingly disease-level aggregated (OMIM, Orphanet, ILAE consensus, systematic reviews, RCTs) rather than individual-patient/EHR. The main EHR-derived signals are the mortality and healthcare-utilization linkage cohorts (e.g., the German claims study).

2. Etiology

LGS is etiologically heterogeneous — the defining feature of the whole entry. Broadly, causes split into identifiable (symptomatic/secondary, ~65–75%) and unknown/cryptogenic (~25–35%, shrinking as genetic testing improves).

Disease causal factors (upstream tributaries): - Structural (the largest identifiable bucket): hypoxic-ischemic encephalopathy, cortical malformations (focal cortical dysplasia, lissencephaly, polymicrogyria, tuberous sclerosis tubers, hypothalamic hamartoma), congenital infections, stroke, trauma, tumors. - Genetic: de novo dominant variants in a long list of DEE genes (see §4). Over 900 monogenic causes of DEEs have been catalogued. - Metabolic/mitochondrial: inborn errors that present as DEE. - Prior epileptic encephalopathy: roughly 10–30% of LGS evolves from West syndrome/infantile spasms — a developmental trajectory rather than an independent cause.

Risk factors: - Genetic: a de novo pathogenic variant in an intolerant DEE gene (SCN2A, STXBP1, CHD2, GABRB3, ALG13, SCN8A, DNM1, etc.). Mostly not "susceptibility loci" in the GWAS sense — these are high-penetrance dominant lesions. - Environmental/perinatal: perinatal hypoxia, prematurity, CNS infection (meningitis/encephalitis), traumatic brain injury in early childhood. - Demographic: age (onset window 1–8 yr, peak 3–5), male sex (modest male predominance), and a prior history of infantile spasms.

Protective factors. No established genetic or dietary protective factors specific to LGS. The nearest analogues are treatment-induced (early seizure control, avoidance of seizure-aggravating drugs). Note: sodium-channel blockers such as carbamazepine, oxcarbazepine, phenytoin, and vigabatrin can worsen myoclonic/absence seizures in LGS — an "anti-protective" iatrogenic factor worth capturing.

Gene-environment interactions. Not well characterized as formal GxE. The relevant interaction is developmental-timing × lesion: the same structural or genetic insult produces LGS specifically when it perturbs the maturing thalamocortical network in the early-childhood window; the identical genotype/lesion at another age yields a different syndrome. This "network maturation state" gating is the closest thing to a GxE story.

3. Phenotypes

LGS is defined by its phenotype cluster. For each, HP-term suggestions and typical characteristics:

Core seizure phenotypes: | Phenotype | HPO suggestion | Notes / frequency | |---|---|---| | Seizures (overall) | HP:0001250 | ~100% (defining) | | Tonic seizures | HP:0032792 | Obligatory hallmark; often nocturnal; ~present in nearly all | | Atypical absence seizures | HP:0007270 | Very frequent (~60–90%) | | Atonic/astatic (drop) seizures | HP:0010819 | Frequent; cause injurious falls | | Myoclonic seizures | HP:0032794 / HP:0001336 | Common | | Generalized tonic-clonic seizures | HP:0002069 | Common | | Nonconvulsive status epilepticus | HP:0002133 (status epilepticus) | Occurs in ~50–75% at some point | | Falls / drop attacks | HP:0002527 | Major morbidity driver |

EEG phenotypes: - Generalized slow spike-and-wave (<2.5–3 Hz): HP:0010845 (EEG with generalized slow spike-and-wave complexes). - Generalized paroxysmal fast activity in sleep: closest is HP:0011198 / HP:0011197 (EEG with generalized epileptiform discharges) — no precise GPFA HP term exists; flag as an ontology gap. - Abnormally slow background rhythm.

Cognitive/behavioral phenotypes: - Intellectual disability: HP:0001249 (progressive; often severe by adolescence). - Global developmental delay: HP:0001263 (frequently precedes/accompanies onset). - Cognitive regression/plateau: HP:0100543 (cognitive impairment). - Behavioral abnormality: HP:0000708; autistic behavior HP:0000729; aggression HP:0000718; ADHD-like inattention/hyperactivity HP:0007018. - Sleep disturbance (recently reviewed as a major, under-recognized burden).

Phenotype characteristics: - Onset: childhood, typically 3–5 yr (range 1–8); onset before age 1 is atypical. - Severity: moderate-to-severe and largely fixed/progressive for cognition; seizure severity fluctuates but is chronically drug-resistant. - Progression: cognitive trajectory is progressive/regressive; seizure semiology evolves with age (tonic seizures may become more prominent in adolescence/adulthood; absences and drops may attenuate). - Frequency among affected: tonic seizures and cognitive impairment approach 100% (definitional); other seizure types are variably present.

Quality-of-life impact. Substantial and multidimensional — injurious drop attacks (fractures, dental/facial trauma, need for helmets), high caregiver burden, dependency, institutionalization risk, sleep disruption, and behavioral comorbidity. Systematic reviews (Orphanet J Rare Dis 2023) document heavy healthcare utilization and among the lowest QoL scores in pediatric epilepsy.

4. Genetic / Molecular Information

Framing: there is no single "LGS gene." LGS is a phenotypic convergence point; genetic testing yields a molecular diagnosis in a substantial minority, mostly de novo dominant variants.

Landmark evidence — the Epi4K exome study (Allen et al., Nature 2013, PMID: 23934111 ✅ verified): whole-exome trio sequencing of 264 probands (149 infantile spasms + 115 LGS) found de novo mutations enriched in genes intolerant to variation, with genome-wide-significant associations for GABRB3 and ALG13. De novo mutations were seen in ≥15% of the cohort.

Causal / recurrently implicated genes (de novo dominant unless noted): - Ion channels (channelopathies): SCN1A, SCN2A, SCN8A, KCNQ2, KCNA2, KCNT1, CACNA1A, HCN1. - GABA-A receptor subunits: GABRB3, GABRA1, GABRG2 — directly implicate inhibitory neurotransmission. - Synaptic / vesicle-trafficking (synaptopathies): STXBP1, DNM1, IQSEC2. - Neuronal migration / cortical development: DCX, FLNA, ARX, LIS1(PAFAH1B1). - mTOR pathway: MTOR, TSC1/TSC2 (tuberous sclerosis), DEPDC5. - Chromatin / epigenetic regulators: CHD2 (≥11 de novo variants reported in DEE incl. LGS), plus others. - Glycosylation / metabolic: ALG13, SLC25A39, and others. - Additional single-case reports (e.g., TANC2 truncating variant, PMID from 2021 case report; NRG2, DNAJC5).

Variant characteristics: - Classification: pathogenic/likely pathogenic per ACMG/AMP (check ClinVar/ClinGen per gene). - Type: predominantly missense and protein-truncating (nonsense/frameshift/splice); also copy-number/structural (via chromosomal microarray). - Allele frequency: de novo variants are absent from population databases (gnomAD) — that absence is part of their pathogenicity argument. - Origin: overwhelmingly germline de novo (arising in parental gametes/early embryo); not inherited in most cases — key genetic-counseling point. - Functional consequence: mixed — loss of function (GABRB3, STXBP1, DNM1, CHD2 haploinsufficiency), gain of function (some SCN2A/SCN8A), and dominant-negative (some GABA-A subunit variants). The GABRB3 N328D knock-in mouse (PMC10179596) is a functional model that reproduces an LGS-like phenotype.

Modifier genes: not systematically defined; the genetic background modulating penetrance/expressivity is an open question.

Epigenetic information: CHD2 (chromodomain helicase) links LGS to chromatin remodeling dysregulation; broader disease-specific methylation signatures are not established. (Search-first: ENCODE, Roadmap.)

Chromosomal abnormalities: chromosomal microarray detects pathogenic CNVs in a subset; large structural lesions and ring chromosome 20 are associated with LGS-like phenotypes (ring 20 classically mimics LGS with nonconvulsive status).

Suggested GO/gene annotations: GABA signaling GO:0007214; regulation of GABAergic synaptic transmission GO:0032228; synaptic vesicle exocytosis GO:0016079; sodium ion transmembrane transport GO:0035725; potassium ion transmembrane transport GO:0071805; neuron migration GO:0001764; TOR signaling GO:0031929; chromatin remodeling GO:0006338. HGNC IDs to bind (lowercase hgnc: per repo convention): SCN2A, STXBP1, CHD2, GABRB3, SCN8A, DNM1, KCNQ2, MTOR, ALG13, etc.

5. Environmental Information

Environmental factors: perinatal hypoxia-ischemia is the most important; also CNS infection (bacterial meningitis, viral encephalitis), traumatic brain injury, and any early-childhood cortical insult. No specific toxin/pollutant is causally established.
Lifestyle factors: not applicable as causes (this is a pediatric encephalopathy); relevant lifestyle domain is management — sleep hygiene, seizure-trigger avoidance, and dietary therapy (§12).
Infectious agents: not a primary infectious disease, but congenital/early CNS infections are among the acquired structural causes. Some cases follow encephalitis. No single pathogen is definitional. (NCBI Taxonomy: not applicable as a defining agent.)

6. Mechanism / Pathophysiology

The unifying model — secondary network epilepsy. The convergent-endpoint view (Archer/Warren and colleagues; Front Neurol 2014, PMID: 24902608; Neurology 2019 "The epileptic network of LGS") holds that regardless of the initiating lesion, LGS manifests through a distributed thalamocortical–brainstem network whose stereotyped failure produces the slow spike-wave and tonic phenomena.

Causal chain (trigger → manifestation): 1. Initiating insult (structural lesion, de novo channel/synaptic/chromatin variant, prior IS) perturbs the developing cortex. 2. Aberrant network maturation — failure of normal synaptic pruning → cortical hyperconnectivity and pathological network behavior; excitation/inhibition imbalance from GABAergic/glutamatergic dysfunction. 3. Secondary bilateral synchrony — focal/multifocal cortical hyperexcitability recruits the whole network, generating generalized slow spike-wave and GPFA discharges. This is why a focal cortical lesion can produce a "generalized"-looking syndrome, and why removing that lesion can abolish the whole process. 4. Thalamus as synchronizer/amplifier, not initiator — EEG-fMRI shows interictal discharges activate brainstem and centromedian/anterior thalamic nuclei; the prefrontal/premotor and frontoparietal association cortices are the peak hubs (bilateral premotor cortex / caudal middle frontal gyrus per fMRI; frontoparietal FDG-PET hypometabolism). This is the rationale for thalamic (centromedian) closed-loop and DBS neuromodulation (Brain Communications 2024, fcae161). 5. Clinical output — multiple generalized seizure types + progressive encephalopathy from chronic network disruption during a critical developmental period.

Molecular pathways / cellular processes: - GABAergic inhibition failure (GABRB3/GABRA1/GABRG2; GABA-A receptor CHEBI:16865 GABA) → reduced inhibitory tone. - Ion-channel dysfunction (SCN2A/SCN8A Nav, KCNQ2/KCNA2/KCNT1 Kv/KNa) → altered GO:0042391 regulation of membrane potential and neuronal firing. - Synaptic vesicle/exocytosis defects (STXBP1, DNM1) → impaired GO:0007268 chemical synaptic transmission. - mTOR hyperactivation (TSC/MTOR) → dysplastic, hyperexcitable cortex (GO:0031929). - Chromatin dysregulation (CHD2) → altered neurodevelopmental gene expression.

Protein dysfunction: loss of function (haploinsufficiency of GABRB3/STXBP1/CHD2), gain of function (Nav channels), dominant-negative (some GABA-A subunits). (UniProt/AlphaFold for structural detail.)

Metabolic changes: frontoparietal glucose hypometabolism on FDG-PET is a robust network signature; specific inborn errors underlie the metabolic-etiology subset. The ketogenic diet's efficacy implicates cerebral energy metabolism shift toward ketone utilization as a therapeutic lever.

Immune involvement: not a primary immune-mediated epilepsy; neuroinflammation is a general seizure-associated process, not a defining mechanism.

Cell types / anatomy (for annotation): - Cell types (CL): neuron CL:0000540, GABAergic interneuron CL:0000617, glutamatergic/pyramidal neuron CL:0000598/CL:0000679, thalamocortical projection neurons. - Anatomy (UBERON): brain UBERON:0000955, cerebral cortex UBERON:0000956, frontal lobe UBERON:0001870, thalamus UBERON:0001897, brainstem UBERON:0002298, corpus callosum UBERON:0002336. (Centromedian thalamic nucleus may lack a precise UBERON term — flag.)

Molecular profiling / advanced tech: most mechanistic traction is from EEG-fMRI, FDG-PET, and network connectivity rather than omics; single-cell/spatial transcriptomic LGS-specific data are sparse. GABRB3 N328D knock-in mice provide the cleanest functional-genomics model.

7. Anatomical Structures Affected

Organ level: brain (primary); nervous system is the sole primary system. Secondary/whole-body effects are consequences of drops (musculoskeletal injury) and chronic disability (respiratory — aspiration; nutritional).
Body systems: central nervous system primarily; secondary musculoskeletal (fall injuries), respiratory (aspiration pneumonia, a leading cause of death), and psychiatric/behavioral.
Tissue/cell level: cortical gray matter (association cortex), thalamic nuclei, brainstem; affected populations are cortical/thalamic neurons and GABAergic interneurons (CL:0000617).
Subcellular level (GO Cellular Component): synapse GO:0045202, presynaptic/postsynaptic membranes, ion-channel complexes at the plasma membrane, synaptic vesicle GO:0008021.
Localization: bilateral, diffuse but frontally/frontoparietally predominant; the network is bilateral and largely symmetric (secondary bilateral synchrony), even when the initiating lesion is unilateral/focal.

8. Temporal Development

Onset: pediatric, typically ages 1–8 (peak 3–5); insidious/subacute, often emerging after or alongside developmental delay, sometimes evolving from West syndrome (~10–30%).
Progression / stages: early phase (emerging multiple seizure types + slowing EEG) → established phase (full triad, tonic seizures dominant, cognitive regression) → adult phase (seizures persist; semiology shifts, tonic seizures and status remain; drops/absences may lessen).
Course: chronic, lifelong, drug-resistant; not relapsing-remitting — persistent with fluctuating seizure burden.
Remission: spontaneous remission is rare (~80–90% continue to have seizures into adulthood). Treatment reduces but rarely abolishes seizures.
Critical period: the early-childhood developmental window is both the vulnerability window and the intervention window — early seizure control is thought to matter for developmental outcome, though drug resistance blunts this.

9. Inheritance and Population

Epidemiology (from Sullivan et al. systematic review, Epilepsia 2024, and burden-of-illness reviews): - Incidence: ~14.5–28 per 100,000 (context-dependent — some figures are cumulative childhood incidence, interpret carefully). - Prevalence: ~5.8–60.8 per 100,000 for probable LGS; ~2.9–28 per 100,000 for narrow/confirmed definitions. Enriched in intellectual-disability populations (~7%, up to ~16% institutionalized). - LGS accounts for 1–4% of all childhood epilepsy but ~10% of epilepsy with onset before age 5.

Genetic epidemiology: - Inheritance pattern: predominantly sporadic / de novo dominant; not classically Mendelian-inherited. A minority reflect inherited structural/metabolic conditions (e.g., tuberous sclerosis = AD; some X-linked genes ALG13, IQSEC2, CDKL5, DCX, FLNA). - Penetrance/expressivity: de novo DEE variants are generally high-penetrance but variably expressive (same gene → different DEE syndromes). - Anticipation: not applicable (not a repeat-expansion disorder). - Germline mosaicism: possible (relevant to recurrence-risk counseling) but low recurrence overall. - Founder effects / consanguinity / carrier frequency: generally not applicable given the de novo/sporadic nature; consanguinity matters only for the rare AR metabolic causes.

Demographics: - Sex ratio: modest male predominance (boys > girls). - Ethnicity/geography: no established ethnic or geographic predilection. - Age distribution: childhood-onset with a lifelong prevalent adult population (survivors persist into adulthood).

10. Diagnostics

Diagnosis is electroclinical — the ILAE 2022 criteria formalize it.

Core diagnostic tests: - EEG (defining): interictal slow spike-and-wave <2.5–3 Hz on a slow background; sleep-activated generalized paroxysmal fast activity (GPFA), the near-specific correlate of tonic seizures. Ictal EEG for tonic/atonic/atypical-absence events. (LOINC: EEG panels.) - Video-EEG / prolonged monitoring to capture the multiple seizure types. - Brain MRI: to identify structural etiology (malformations of cortical development, hypoxic injury, tubers). (RadLex/Radiopaedia.) - FDG-PET: frontoparietal hypometabolism (supportive/network, not diagnostic).

Etiologic workup (genetic testing): - Chromosomal microarray (CMA) for CNVs; karyotype/FISH for ring chromosome 20 and other structural anomalies. - Epilepsy gene panels / whole-exome sequencing (WES) — highest yield; trio WES best for de novo detection. Whole-genome sequencing (WGS) increasingly used. - Metabolic workup / mitochondrial testing when metabolic etiology suspected. - GeneReviews / GTR / ClinGen for gene-level interpretation.

Clinical criteria: ILAE 2022 syndrome definition requires the seizure-type + EEG + cognitive triad, with tonic seizures and/or GPFA carrying strong diagnostic weight.

Differential diagnosis (key mimics to rule out): - Epilepsy with myoclonic-atonic seizures (Doose syndrome) — myoclonic-atonic predominant, better prognosis, no tonic seizures/GPFA. - Dravet syndrome — SCN1A, fever-sensitive, earlier onset. - Atypical benign partial epilepsy / pseudo-Lennox — better outcome. - Ring chromosome 20 epilepsy, continuous spike-wave in slow sleep (CSWS), West syndrome (may precede LGS).

Screening. No population newborn screen for LGS itself; relevant genetic causes may surface on expanded newborn screening or carrier screening only for the specific metabolic/monogenic subset.

11. Outcome / Prognosis

Prognosis is unfavorable but variable. ~80–90% continue to have seizures into adulthood; cognitive impairment is usually permanent and often progressive.
Mortality: significantly elevated vs. general population. A German linkage cohort reported ~2.88% mortality over 10 years vs. ~0.01% in age-matched controls — an ~orders-of-magnitude excess. Causes include SUDEP (sudden unexpected death in epilepsy), status epilepticus, aspiration pneumonia, and injury from drop attacks.
Morbidity/disability: severe — intellectual disability, dependency, injurious falls, behavioral comorbidity, high institutionalization rate. Among the highest disability burdens in pediatric epilepsy (GBD/ICF framing).
Prognostic factors (worse outcome): early onset, evolution from West syndrome, symptomatic/structural etiology, high tonic-seizure and status frequency, early cognitive impairment. Cryptogenic cases with later onset and no prior IS tend to fare relatively better.
QoL measures: disease-specific and generic tools (caregiver-reported) consistently show low scores; drop-seizure frequency is a key modifiable QoL driver (hence trial endpoints focus on drops).

12. Treatment

Goal: seizure-burden reduction (especially injurious drops) and QoL — not cure. Polytherapy is the norm; drug resistance is expected.

Pharmacotherapy — FDA-approved for LGS (8 agents; approval years): clonazepam (1975), felbamate (1993), lamotrigine (1998), topiramate (2001), rufinamide (2008), clobazam (2011), cannabidiol (2018), fenfluramine (2022). Valproic acid is common first-line broad-spectrum background therapy (widely used, not LGS-labeled).

Landmark trial evidence (verified): - Cannabidiol (Epidiolex), CHEBI:69478 — GWPCARE4 (Thiele et al., Lancet 2018, PMID: 29395273 ✅) and GWPCARE3 (Devinsky et al., NEJM 2018, PMID: 29768152 ✅): add-on CBD significantly reduced drop-seizure frequency vs. placebo; 2024 consensus panel (Epilepsia Open) optimizes dosing. Modality: SMALL_MOLECULE (phytocannabinoid). - Fenfluramine (Fintepla), CHEBI:5000 — Knupp et al., JAMA Neurol 2022;79(6):554–564, PMID: 35499850 ✅ verified: RCT, n=263; 0.7 mg/kg/d gave 26.5% median drop-seizure reduction vs. 7.6% placebo (P=.001); no valvular heart disease or pulmonary hypertension observed. Open-label extension (Knupp, Epilepsia 2023, PMID: 36196777 ✅) confirmed durable benefit. - Rufinamide, CHEBI:32219 — pivotal RCT (Glauser et al., Neurology 2008) established efficacy for drop attacks. ⚠️ PMID from memory ~18936427/18401024 — verify with just fetch-reference before curation. - Lamotrigine — Motte et al., NEJM 1997. ⚠️ Verify PMID. - Felbamate — Felbamate Study Group, NEJM 1993 (efficacy strong but limited by aplastic anemia/hepatotoxicity risk). ⚠️ Verify PMID. - Topiramate — Sachdeo et al., Neurology 1999. ⚠️ Verify PMID. - Clobazam, CHEBI:31401 — Ng et al., Neurology 2011 (pivotal). ⚠️ Verify PMID.

Emerging / off-label pharmacotherapy: - Cenobamate — retrospective/real-world adult and pediatric LGS series show meaningful drop-seizure reduction and enable clobazam dose reduction (PMC9821211, PMC12255617, 2023–2024). Not yet LGS-labeled. - Soticlestat (CH24H inhibitor) — phase-3 signal in LGS was a nonsignificant numerical reduction in drops (contrast with positive Dravet data); development context evolving. - Low-dose fenfluramine in adults (PMC12317795, 2024). - 2024 consensus treatment algorithm published (Epilepsy & Behavior, S1525-5050(24)00643-7).

Pharmacogenomics: relevant at the drug-safety level — e.g., HLA-linked risk for lamotrigine cutaneous reactions (SJS/TEN); CYP-mediated clobazam metabolism (CYP2C19). Emerging precision therapy matches the molecular etiology to mechanism (e.g., sodium-channel-blocker avoidance in some, targeted approaches for mTOR/GABA-A variants). (IJMS 2025 precision-therapeutics review, PMC12025602.)

Non-pharmacologic / interventional: - Ketogenic diet (MAXO:0000088 dietary intervention as fallback term; check for a specific MAXO ketogenic term): ~50% of patients achieve >50% seizure reduction; some >90%. - Vagus nerve stimulation (VNS): ~50% responder rate (>50% reduction), improving over time; palliative. - Corpus callosotomy (MAXO:0000004 surgical procedure): most effective option for injurious drop attacks — disconnects interhemispheric spread. Systematic review/meta-analysis supports callosotomy + diet efficacy (Child's Nerv Syst 2021). - Thalamic (centromedian) DBS / closed-loop stimulation: emerging neuromodulation targeting the network hub (Brain Communications 2024). - Resective surgery when a focal structural lesion drives the network. - Supportive/rehabilitative: helmets for drop protection, PT/OT/speech (MAXO:0000950 supportive care; NCIT:C15315 rehabilitation), behavioral and sleep management.

Advanced therapeutics (experimental): gene-targeted/ASO approaches are on the horizon for specific monogenic causes (STXBP1, SCN2A, etc.) but not yet LGS-syndrome therapies. ClinicalTrials.gov (e.g., NCT03936777 fenfluramine long-term safety) for active programs.

MAXO/NCIT term suggestions: pharmacotherapy NCIT:C15986 (with therapeutic_agent CHEBI drugs); dietary intervention MAXO:0000088; surgical procedure MAXO:0000004; supportive care MAXO:0000950; genetic counseling MAXO:0000079. VNS and ketogenic-diet-specific MAXO terms should be looked up with OAK.

13. Prevention

Primary prevention: limited — reduce acquired causes via good perinatal care (preventing hypoxic-ischemic injury), CNS-infection prevention/vaccination, and TBI prevention. No vaccine or lifestyle intervention prevents LGS directly.
Secondary prevention: early recognition and control of infantile spasms/West syndrome may reduce evolution to LGS (an active hypothesis and management priority); early EEG in a child with developmental delay + new seizures for prompt diagnosis.
Tertiary prevention (complication avoidance): the practical core — drop-injury prevention (helmets, callosotomy), SUDEP-risk mitigation (seizure control, nocturnal monitoring), aspiration/nutrition management, avoiding seizure-aggravating ASMs (carbamazepine, oxcarbazepine, phenytoin, vigabatrin).
Genetic counseling (MAXO:0000079): for families with an identified de novo variant, recurrence risk is generally low (low-level germline mosaicism caveat); for inherited causes (TSC, X-linked genes) counseling is more consequential. Prenatal/preimplantation testing applies only when a specific familial variant is known.
Screening: no population screen; cascade/prenatal testing only for the monogenic/structural subset.

14. Other Species / Natural Disease

Taxonomy: LGS as a defined electroclinical syndrome is essentially human-specific (NCBITaxon:9606). There is no recognized naturally occurring LGS in other species (OMIA has no LGS entry).
Comparative biology: the mechanisms are conserved — epilepsy and the underlying channel/synaptic genes have clear orthologs. Mouse models of specific genes (GABRB3, SCN2A, etc.) recapitulate seizure/encephalopathy features but not the full human syndrome (human association-cortex network complexity isn't reproduced).
Zoonotic potential: none (non-infectious, non-transmissible).

This section is largely N/A — LGS is a human network-epilepsy syndrome; the comparative angle lives entirely in the model-organism domain below.

15. Model Organisms

Model types: predominantly mammalian (mouse) gene-specific models; also zebrafish for channel/high-throughput drug screening; iPSC-derived neurons/organoids for synaptic phenotyping; in vitro electrophysiology of variant channels/receptors.
Genetic models: knock-in (point-mutation), knockout, and conditional/humanized alleles of DEE genes.
Flagship example: GABRB3 N328D heterozygous knock-in mouse (PMC10179596) — reproduces an LGS-like phenotype (multiple seizure types, EEG abnormalities, behavioral/cognitive deficits), one of the better syndrome-level recapitulations. Other models: Scn2a, Scn8a, Stxbp1, Dnm1 (fitful mouse), Chd2, Cdkl5, Alg13 mice — each captures a slice of the phenotype.
Phenotype recapitulation: single-gene models reproduce seizures, EEG discharges, and neurodevelopmental deficits, and are used for mechanism and drug testing. Limitation: none fully reproduces the human syndrome's distributed frontoparietal network dysfunction and cognitive regression — a HUMAN_MODEL_MISMATCH-flavored gap worth flagging in the KB (evidence exists in models but the network-level, association-cortex biology is human-specific).
Applications: genotype-specific pathophysiology, ASM screening, precision-therapy proof-of-concept (e.g., gene-targeted approaches).
Resources: MGI, IMPC/KOMP, ZFIN, Alliance of Genome Resources; Cellosaurus for iPSC lines.

Curation notes & caveats for the KB entry

Evidence-source tagging: the RCTs (fenfluramine, CBD) are HUMAN_CLINICAL; the GABRB3 N328D mouse is MODEL_ORGANISM; variant-channel electrophysiology is IN_VITRO; network/PET modeling papers are HUMAN_CLINICAL or COMPUTATIONAL depending on method. Keep model-organism evidence distinct from human phenotype claims.
Verified PMIDs (safe to seed): 23934111 (Epi4K), 35499850 (fenfluramine RCT), 36196777 (fenfluramine OLE), 29395273 (CBD GWPCARE4), 29768152 (CBD GWPCARE3), 24902608 (secondary network epilepsy).
PMIDs to verify before use (from memory): the older ASM pivotal trials (rufinamide/Glauser, lamotrigine/Motte, felbamate, topiramate/Sachdeo, clobazam/Ng). Run just fetch-reference and confirm exact-quote snippets — don't trust my recalled numbers.
Identifier flags: MONDO:0016532 (verify via local sqlite:obo:mondo; watch the OLS cache-miss issue), OMIM 606369 is a soft/heterogeneous mapping, ORPHA:2382 confirmed.
Ontology gaps to note: no precise HP term for generalized paroxysmal fast activity; centromedian thalamic nucleus may lack a UBERON term; ketogenic-diet/VNS MAXO terms need OAK lookup.
Module conformance opportunity: LGS is a natural conformer for epilepsy_excitation_inhibition_imbalance (key node #Excitation-Inhibition Imbalance) — the E/I-imbalance → hyperexcitability → seizure chain maps cleanly, with LGS substituting the secondary-bilateral-synchrony/thalamocortical-network specialization.

Primary sources drawn on: - Allen et al., De novo mutations in epileptic encephalopathies, Nature 2013 (PMID 23934111) - Knupp et al., Fenfluramine RCT in LGS, JAMA Neurol 2022 (PMID 35499850) - Knupp et al., Fenfluramine OLE, Epilepsia 2023 (PMID 36196777) - Thiele et al., Cannabidiol GWPCARE4, Lancet 2018 (PMID 29395273) - Devinsky et al., Cannabidiol GWPCARE3, NEJM 2018 (PMID 29768152) - Archer et al., LGS as secondary network epilepsy, Front Neurol 2014 (PMID 24902608) - Sullivan et al., Global epidemiology of Dravet & LGS, Epilepsia 2024 - Burden of illness in LGS systematic review, Orphanet J Rare Dis 2023 - Precision Therapeutics in LGS, IJMS 2025 (PMC12025602) - GABRB3 N328D knock-in mouse LGS model (PMC10179596) - Targeting thalamocortical circuits for closed-loop stimulation in LGS, Brain Commun 2024 - Orphanet: Lennox-Gastaut syndrome (ORPHA:2382) - Diagnosis of LGS and early recognition, Expert Rev Neurother 2024

That's the whole delta mapped — tributaries, the swampy convergence point, and the levees we've got to hold it back. The single most load-bearing idea for the KB is that "cause" and "syndrome" live at different altitudes here: curate the many upstream etiologies as distinct genetic/structural nodes, but let them all drain into the shared secondary-network-epilepsy mechanism. Want me to go ahead and scaffold the actual kb/disorders/Lennox-Gastaut_Syndrome.yaml entry from this, or run the MONDO/OMIM identifier verification first?

Lennox-Gastaut Syndrome

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Progression

Prevalence

Epidemiology

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Curation notes & caveats for the KB entry